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ABSTRACT 
Dendritic cells (DCs) are crucial antigen-presenting cells that can drastically change 
the development of an immune response by polarising T helper cells toward a Th1 
or a Th2 phenotype. Heligmosomoides polygyrus, a murine model of human 
helminth, has been shown to strongly down-regulate its host immune response. At 
the DC level, its excretory/secretory products (HES) modulate the cytokine response 
and co-stimulatory marker expression to bacterial stimulation in favour of an anti-
inflammatory environment. A regulatory T cell-inducing TGFβ-like activity was also 
discovered in HES. 
In this work, we further characterised the immunomodulatory properties of HES and 
heat-inactivated HES both in vitro, using LPS-pulsed GM-CSF-grown bone marrow-
derived DCs, and in in vivo adoptive transfer of HES-, bacterial extract- or co-pulsed 
DCs. To determine if the TGFβ, C-type lectin receptors (CLRs) or toll-like receptors 
(TLRs) were implicated in this immunomodulation, we treated DCs with blocking 
antibodies, chemical kinase inhibitors and grew DCs from knockout mice. These 
studies revealed that HES immunomodulation of DCs was independent of the TGFβ 
receptor, the two CLRs, Dectin-1 and 2, as well as any TLR. Spleen tyrosine kinase 
(Syk), which is crucial for the signalling of many CLRs, and phosphoinositide 3-
kinase seemed not to be needed as well. 
In an attempt to reduce the number of potential immunomodulators in HES, HES 
size fractions were tested for their ability to reduce LPS-induced inflammatory 
cytokine production of DCs. The activity was limited to few fractions, fraction 14 
being the most potent. 
Finally, physical interactions between DCs and biotinylated HES were measured by 
flow cytometry and revealed that CD24, a molecule required for HES interactions 
with B cells, was implicated, but not crucial. HES binding to CD24-/- DCs was 
reduced, but the LPS-induced cytokines and co-stimulatory markers levels were still 
down-regulated upon HES co-treatment. 
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1 
1 Introduction 
1.1 Helminth	  infections	  
The word helminth comes from the Greek meaning worms and describes a class of 
parasitic worms that live inside their host [1]. These parasites can have more or less 
complex life cycles involving one or two host species. Although, most of the 
infections by helminths are non lethal, their burden on the populations of developing 
countries is huge. In order to measure it, the concept of disability-adjusted life years 
(DALYs) was developed by the World Health Organisation (WHO) in 1990. Each 
disease was assigned a number of DALYs, which correspond to the sum of the 
average number of life years infected people will lose due to premature death and 
the average number of life years infected people will suffer from the disease and 
therefore lose their productivity. According to the first WHO report on neglected 
tropical diseases [2] released in 2010, more than one billion human beings are 
infected by helminths worldwide and these infections are estimated to be 
responsible for more than 17 million DALYs. 
Helminthiases can affect cognitive functions and vision, but also cause deformity 
and skin diseases. Children are especially affected as they suffer from growth 
stunting and have difficulties focusing at school. Pregnant women have a higher risk 
of neo-natal prematurity and pregnancy-associated mortality [1]. All these symptoms 
are responsible for a high morbidity that prevents poor regions from improvement of 
their economical situation. Nevertheless, these diseases kill less than the “big three” 
(AIDS, tuberculosis and malaria) and are confined to the poorest countries in the 
world as they thrive in low hygiene standards and a tropical climate. This low 
visibility in developed countries and the lack of interest for the industry to invest in 
treatments against diseases affecting mostly poor populations resulted in very low 
funding for research in this topic [2]. 
A key feature of helminth infection is that, as opposed to bacteria or viruses, worms 
do not replicate at high rate inside their host. Thus, the intensity of the infection 
depends on the number of eggs or larvae to which the host is exposed. For the 
helminths themselves, the critical aspect is their ability to stay alive for a long period 
inside their host, in order to produce as many eggs as possible. For this purpose, 
worms must counteract or evade the immune system of their host and some are 
quite successful indeed. In most cases, immunity to this kind of organism arises only 
2 
after several years, showing the incredible ability of helminths to down-regulate their 
host’s immune response. 
1.2 Mammalian	  immune	  response	  to	  helminth	  infections	  
Dealing with macro-organism producing eggs has little in common with defence 
against microorganisms such as bacteria or viruses that replicate at high frequency. 
Therefore, the mammalian immune system has evolved in order to discriminate 
different kinds of parasites and set up an appropriate response for each of them. 
The adaptive T helper (Th) 1-type response is optimized to clear intra-cellular 
parasite infections. Th1 cells help infected macrophages to kill ingested pathogens 
and induce the production of immunoglobulin (Ig) G2 by B-lymphocytes. In this 
setting, cytotoxic CD8+ T cells proliferate rapidly to kill infected cells. This type of 
response is associated with tissue damage and can be more dangerous than helpful 
if the infection is not quickly contained and cleared. If the pathogen manages to 
evade the host defences and survives for extended periods, activated immune cells 
will stay in the infected tissues and the constant exposition to high doses of 
inflammatory signals will prevent tissue repair and healing. Chronic inflammatory 
diseases such as autoimmune disease or septic shock, resulting from a cytokine 
storm, are amongst the adverse effects that can arise from an uncontrolled Th1 
response. The Th2-type response is more dedicated to the protection against extra-
cellular parasites. In this setting, B cells produce IgE and IgG1, mast cells, basophils 
and eosinophils are recruited to the site of infection and increased epithelial cell 
turnover and mucus production are favoured. Thus, The type-2 response is more 
associated with tissue remodelling and repair [3]. Moreover, smooth muscles are 
activated and can help to expel intestinal parasites in combination with increased 
mucus flow [4]. In addition, another type of CD4+ T cells recently turned out to be 
important for mucosal immunity. Th17 have been reported to be involved in the 
protection against different extra- and intra-cellular bacteria as well as fungal 
infections [5]. Finally, a negative signal, determined by so-called regulatory T cells 
(Tregs), is necessary to avoid bursts of inflammatory cytokines, extended tissue 
destruction and allow the return to a resting state after the pathogen clearance. 
Although the Th2 response stays the most efficient way of clearing parasites such 
as intestinal worms, most helminths require a good balance between Th1, Th2 and 
the regulatory response in order to be cleared [6]. A strong Th1 response should 
definitely be avoided, as it implies chronic inflammation, but if the regulatory 
response dominates, parasites will survive inside the host for an extended period. In 
3 
the case of H. polygyrus however, the susceptibility of mouse strains seems to be 
correlated with the ability to quickly mount a strong Th2 response to the worm 
(unpublished data Filbey et al.). 
1.3 The	  life	  cycle	  of	  Heligmosomoides	  polygyrus	  
Heligmosomoides polygyrus bakeri is a rodent gut parasite with a fairly 
straightforward life cycle. The eggs are spread in the environment via the faeces of 
the host. Thirty-six hours after being laid, eggs hatch, giving way to the first larval 
stage (L1). Two successive moults, will then give rise to second (L2) and third (L3) 
larval stages. L3 larvae are infective and can invade the duodenal mucosa if a 
suitable host ingests them. Two more moults inside the gut mucosa are needed 
before the parasites can move back into the intestinal lumen as adult worms, about 
8 days after infection. Two days later, the first eggs can be detected in the newly 
infected host’s faeces. Altogether, the cycle takes about 13.5 days, but once a 
rodent is infected, the female worms can survive up to 8 months in the lumen of its 
duodenum depending on the strain of the host [7] (http://hpoly.blogspot.com/). The 
excretory/secretory products of H. polygyrus (HES) are derived from adult worm 
cultures by filtrating the supernatant in order to collect only the secreted molecules. 
1.4 Dendritic	  Cells	  and	  the	  polarisation	  of	  the	  immune	  response	  
Dendritic cells play a central role in the organisation of the immune system, as they 
provide the crucial link between innate and adaptive immunity. While immature, they 
sample their environment by taking up antigens through endocytosis. If a danger 
signal, like pathogen-associated molecular patterns (PAMPs) or molecules secreted 
during necrosis, for example, is present in the tissue, DCs acquire the ability to 
migrate to secondary lymphoid organs where they can find and activate CD4+ T 
cells [8]. By doing so, they can polarise naïve CD4+ T cells to different types of 
immune response, including the Th1 response, characterised by interferon (IFN) γ 
production, the Th2 response, showing a strong interleukin (IL)-4 production, or the 
Th17 response, defined by IL-17 production. Interestingly, DCs are able to associate 
one particular response to several different antigens simultaneously, by trafficking 
them in different cellular compartments [9]. 
All dendritic cells are derived from bone marrow stem cells, but two main subsets 
can be distinguished in humans. The CD34+ myeloid progenitors give rise to CD14-
CD11c+ cells, also called “classical” pre-DCs, whereas the CD34+ lymphoid 
progenitors give rise to a CD11c-IL3Rα+ subpopulation, known as “plasmacytoid” 
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DCs [10]. While classical pre-DCs are reported to express the Toll-like receptor 
(TLR) 2 and TLR 4 and produce inflammatory cytokines like tumor necrosis factor 
(TNF) α, IL-6 and IL-12, plasmacytoid pre-DCs (pDCs) are known to express TLR7 
and TLR9 and produce large amount of IFN-α [11]. 
In the mouse model, similar populations have been reported. Their respective TLR 
expression remains the same, but classical DCs were described as CD11chiB220-
MHCII+ and the pDCs as CD11cintB220+. In vivo equivalents of these subsets can be 
obtained by in vitro culture of bone marrow derived DCs (BMDCs), containing either 
granulocyte macrophage-colony stimulating factor (GM-CSF) which induces TLR4-
expressing cDCs [8], or Flt3 ligand (Flt3L) which induces TLR9 expressing pDCs. In 
different microenvironments, these pDCs are though to induce Th1-, Th2-type 
responses, as well as Foxp3+ regulatory T cells [10]. 
In order to activate T cells, DCs must express MHC class II to present antigens to 
the T cell receptor (TCR), but they must also express co-stimulatory surface 
molecules, such as CD80, CD86 or CD40 that will provide a co-stimulatory signal to 
confirm that an immune response must be mounted against the presented antigen 
[8]. CD40 has been shown necessary to drive Th2 induction in vitro [12] and the 
expression of these surface molecules can be modified after TLR ligation [13]. 
Therefore, these molecules are good indicators of the activation state of the 
dendritic cell and interesting targets for flow cytometry analysis. 
In addition, to these two signals, the cytokine cocktail surrounding the T cell can 
polarise it toward one of the T-helper or toward the regulatory phenotype. Therefore, 
the cytokines produced by the activated DC, along with those produced by the other 
innate and adaptive immune cells present in the lymph node at the moment of the 
antigen presentation, are crucial for the development of an appropriate response (or 
tolerance) to the presented antigen. It is now known that Th1 response is induced 
by the release of IL-12 while IL-6 and transforming growth factor (TGF)-β are 
needed to drive a Th17 response. Unfortunately, no Th2-driving cytokine has been 
clearly identified until now as IL-4- and IL-10-deficient DCs have still the ability to 
drive Th2 response [14]. Nevertheless, type-2 immunity is characterized by the 
release of IL-4, IL-5, IL-9, IL-13 and IL-21. Finally, IL-10 displays strong anti-
inflammatory properties [15]. 
In 2008, Andrew MacDonald and Rick Maizels reviewed three different models to 
describe the Th1/Th2 polarisation induced by DCs [14]. The first one is the 
maturation model, in which Th2 response is driven “by default” when DCs are 
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activated in the absence of a TLR ligand. In the second one, called alternate 
pathway model, the decision is taken downstream of the pattern recognition 
receptor (PRR) through a competition between a MyD88-dependent Th1-inducing 
pathway and a Th2-inducing signalling pathway. Finally, the inhibition model 
proposes a cross-inhibition between the two signalling cascades. According to this 
review, the two later models better fit the dynamics of the adaptive immune 
response and allow its fine tuning. However, experimental evidence is lacking to 
validate one or more of these models. 
Furthermore, the polarisation of the adaptive immune response is not a 
straightforward process. DCs do not only interact with T cells but probably with a 
broad range of other immune cells, which could modulate the activation state of DCs 
throughout the maturation and T cell activation processes. Moreover, the molecular 
environment of the DCs, which integrate cytokine and chemokine productions from 
many immune and non-immune cell types, certainly plays a similar role. This is why 
the authors of this review mention that the Th2-driving signal could possibly come 
from other cell types. 
1.5 Molecular	  basis	  for	  the	  recognition	  of	  foreign	  molecular	  patterns	  
From a molecular point of view, PAMPs can be detected by different pattern 
recognition receptors (PRRs). These receptors can be cytoplasmic, like nucleotide-
binding oligomerization domain-containing protein (NOD)-like receptors, membrane 
associated, like TLRs and C-type lectin receptors (CLRs), or even secreted. 
Following PRR activation, the downstream signalling cascade leads to a change in 
the activation state of the DCs resulting in their migration to the lymph nodes and 
the involvement of the adaptive immune system. These modifications are relatively 
easy to detect as they alter cytokine production profile and cell surface marker 
expression. 
Among the pattern recognition receptors, the TLR family is the most studied and 
best understood. These trans-membrane molecules have the ability to recognise a 
broad variety of pathogens and pathogenic products. For example, TLR4 can detect 
lipopolysaccharide (LPS) present on Gram-negative bacteria, whereas TLR9 links 
unmethylated CpG that are not found on mammalian DNA [16]. TLR signalling 
activation can also be achieved with small synthetic compounds that mimic PAMPs. 
Examples are Pam3CSK4 (Pam3), a lipopeptide that binds TLR2 [17], and R848, a 
known TLR7/8 ligand [18].  
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Remarkably, members of the TLR family share two main adapter proteins directly 
downstream of the receptor. These two molecules are called myeloid differentiation 
primary response gene 88 (MyD88) and Toll/Interleukin 1 receptor (TIR)-domain-
containing adapter-inducing interferon-β (TRIF). MyD88 is involved in the signalling 
of almost all TLRs and most of them are totally dependent on this molecule to 
induce the activation of the cell [16]. The double-stranded RNA binding TLR3, 
however, is not dependent on MyD88, but on TRIF only. The TRIF pathway is also 
an alternative signalling route for TLR4 [19]. The homeostasis of this system is 
really interesting, as it seems to auto-regulate. On one hand, the recruitment of 
adaptor molecules such as MyD88 or TRIF results in the activation of the mitogen-
activated protein kinase (MAPK) and NF-κB pathways and therefore in the 
expression of pro-inflammatory genes. On the other hand, Ojaniemi et al. [20] 
showed that MyD88 constitutively binds the p85 regulatory subunit of 
phosphoinositide 3-kinase (PI3K), but that this interaction is further enhanced upon 
LPS ligation leading to the conversion of phosphatidylinositol (4,5)-bisphosphate 
(PIP2) into phosphatidylinositol (3,4,5)-trisphosphate (PIP3) by PI3K. Despite the 
fact that the activation of the PI3K/Akt/mTOR signalling pathway can have both pro- 
and anti-inflammatory effects, there is growing evidence that, in myeloid DCs, this 
pathway can prevent an over-activation that could lead to a cytokine storm by down-
regulating pro-inflammatory cytokines production and enhancing IL-10 production 
[21-23]. Moreover, Laird et al. [24] have proposed a complementary negative 
feedback mechanism according to which the consumption of PIP2 near the 
activated TLR would reduce the Toll/interleukin-1 receptor (TIR) domain-containing 
adapter-like (TIRAP) dependent recruitment of MyD88 on TLR4, therefore reducing 
the activation of the NF-κB pathway and the inflammatory cytokine production. A 
simplified schematic of the main molecules involved in the TLR and CLR pathways 
is available at the end of this document (Appendix Fig. S 9). 
A deregulation of this balance in favour of the regulatory pathway would, of course, 
be very useful for any pathogen. Interestingly, interactions between helminth 
products and the TLR pathway to diminish inflammation have already been 
described. Although this paper has been retracted in the meantime, Puneet et al. 
[25] showed in February 2011 that ES-62, produced by Acanthocheilonema viteae, 
was able to induce the degradation of MyD88 by autophagosomes, therefore limiting 
inflammatory cytokines production and increasing mice survival in a septic shock 
model. The PI3K pathway has also been shown to be critical for the down-regulation 
of LPS-induced IL-12 by another intestinal parasite Giardia lamblia [26]. 
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As opposed to TLRs that recognise a broad range of pathogen-associated patterns, 
classical CLRs are specialised in the detection of carbohydrates containing patterns. 
The binding sites of their carbohydrate recognition domain (CRD) are dependent on 
Ca2+ availability in the extra-cellular environment [27]. Not all CLRs act as PRR, but 
those that do can either induce or inhibit cellular activation. To this end, CLRs 
transmit the extra-cellular signal through their immunoreceptor tyrosine-based 
inhibitory motif (ITIM) or activation motif (ITAM). Those consensus domains can be 
found on the cytoplasmic tail of some CLRs, like Dectin-1, but other CLRs, like 
Dectin-2 or Mincle, do not possess such a tail. They must, therefore, associate with 
an adaptor molecule, such as DAP12 or the FcRγ chain that possess 
immunoreceptor tyrosine-based motives. Upon ligation of the CLR, these motifs get 
phosphorylated and can then be bound by Src homology 2 (SH2) domain containing 
enzymes. Most frequently, molecules of the spleen tyrosine kinases (Syk) family 
bind ITAM domains, leading to the activation of the cell through the NF-κB pathway. 
On the other hand, ITIM phosphorylation induces the recruitment of phosphatases 
that antagonise the activating kinases [28, 29]. However, cases of ITAM mediating 
inhibition and ITIM mediating activation have also been reported [30]. 
This ability of CLRs to modulate the activation state of the immune cells is of great 
interest in the search for cellular receptors targeted by H. polygyrus in order to 
manipulate the immune response of its host. The potential role of CLRs in this 
process is supported by the fact that the binding of other helminth products to CLRs 
has already been described. For example, Ritter et al. [31] have shown that 
schistosomal egg antigens (SEA) can induce IL-1β through Dectin-2, Syk kinase 
signalling and Nlrp3 inflammasome activation. Syk is a particularly interesting target 
as it is widely present in the signalling pathways of the different CLRs [32]. 
However, some CLRs, like Dectin-1 can also signal through a Syk independent, 
Raf-1 dependent pathway [33] (Fig. S 9). 
Pathogen associated molecular patterns are not the only type of molecules that can 
activate the innate immune system. Some non-foreign molecules share this ability. 
They are called danger-associated molecular patterns (DAMPs) and are up-
regulated in case of tissue damage or can be released by activated or necrotic cells. 
Similarly to PAMPs, DAMPs can bind to TLRs and induce an inflammatory 
response. However, the cell activation outcome is somehow different in terms of 
cytokine production and antigen presentation [34]. These differences could be due 
to alternative co-receptors and accessory molecules in the TLR signalling pathway 
itself [34], but, in 2009, Chen et al. [35] proposed a new mechanism allowing to 
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discriminate PAMPs and DAMPs through a specific down-regulation of the response 
to DAMPs. According to their paper, the ligation of DAMPs, such as high mobility 
group box 1 (HMGB1) or heat shock proteins (HSPs), by a complex formed by 
CD24 and a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) 
family could selectively inhibit the NF-κB pathway through the interaction of the Src 
homology region 2 domain-containing phosphatase (SHP) -1 with the ITIM domain 
of Siglec-G. This model could avoid an inflammation of a sterile wound while 
allowing a quick inflammation if PAMPs were detected. However, it could also be a 
good target to hijack for a pathogen trying to keep the immune system in a non-
activated state. 
1.6 The	  known	  immunomodulatory	  effects	  of	  HES	  
H. polygyrus derived excretory/secretory products are numerous and diverse. A 
mass spectrometry analysis performed in the lab revealed that no less than 374 
different proteins are found in the HES. Nevertheless proteins are not the only 
components of HES. Carbohydrates, glycans or other small molecules could also be 
able to modify the immune response to H. polygyrus. Moreover, some of these 
molecules are very abundant, but others can be expressed at low level while 
remaining biologically active [36]. This makes the molecular analysis of HES a 
complex task. 
Therefore, many research groups have studied the global immunomodulatory 
effects of HES as a whole. In their paper [37], Segura et al. mention that HES does 
not induce DC maturation or cytokine production nor modifies antigen uptake and 
processing. On the contrary, it seems to down-regulate the inflammatory cytokine 
production of in vitro cultured BMDCs stimulated with different TLR ligands. These 
results were confirmed in vivo by adoptive transfer of OVA-pulsed BMDC pre-
treated with HES. Three weeks after the transfer, the OVA-specific antibody 
response and the IgE level were significantly reduced in mice that had received 
HES pre-treated BDMC compared to those that received naïve BDMC. Another 
remarkable effect described in this paper, is the ability of HES treated BMDCs to 
induce the generation of IL-10 producing CD4+CD25+Foxp3- T cells when co-
cultured with naïve CD4+ T cells. In these cultures, the levels of IL-4 and IFNγ were 
also strongly diminished. The regulatory function of these CD4+ T cells was 
confirmed by culturing them with effector T cells and the results show that CD4+ T 
cells co-cultured with HES pre-treated DCs were able to reduce the proliferation of 
effector T cells. Finally, as opposed to other helminth ES products [38], HES was 
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still able to down-regulate IL-12p70 produced by CpG stimulated BMDCs lacking 
TLR 2 or TLR 4, arguing against a direct recognition of HES by those TLRs. 
In his thesis at Rick Maizels’ laboratory, John R. Grainger, confirmed some of 
Segura’s results. He showed in particular that HES pre-treated BMDCs stimulated 
with LPS in vitro produce less IL-12p70 than naïve BMDCs in a concentration 
dependent manner. Similarly, HES was able to limit the up-regulation of CD40 and 
CD86 on the DC surface in this setting. In order to discriminate the effects of heat-
labile and heat-stable components of HES, Grainger performed the same 
experiments with heat-inactivated HES (hiHES). Again, on its own hiHES did not 
induce any inflammatory cytokines or cell surface markers up-regulation, but the 
immunomodulatory properties of HES were disrupted by the heat treatment. This 
result also suggests that there is no endotoxin contamination of the HES as these 
molecules are heat-stable. 
Moreover, referring to Cervi’s work [9], Grainger performed an in vivo transfer 
experiment in which BMDCs were pulsed with HES, hiHES, a bacterial extract from 
Propionibacterium acnes (Pa) or a combination of these products to determine if 
HES was able to skew the adaptive response to a strong Th1 inducer. Before the 
transfer, HES but not hiHES, was able to down-regulate the Pa-induced 
inflammatory cytokine production and cell surface marker up-regulation as 
previously observed with LPS. Seven days after the transfer, Grainger re-stimulated 
splenocytes with HES or Pa and observed that HES-pulsed DCs induced a Th2-type 
response whereas Pa-pulsed DCs induced an IFN-γ/IL-17 rich environment. Heat-
inactivated HES showed the same pattern as HES. The co-pulsed groups showed a 
HES (or hiHES)-specific Th2 and Pa-specific Th1 responses, but no HES-specific 
Th1 or Pa-specific Th2 responses. Interestingly, the cytokine levels in the co-pulsed 
groups were much lower than in the groups pulsed with only one antigen with the 
remarkable exception of HES-specific IL-17 production that reached the same 
extend as Pa-specific IL-17 in the HES/Pa co-pulsed group. 
Grainger also studied the influence of HES on the T cell pool, but his research was 
focussed on Foxp3+ regulatory T cells. Grainger showed that the percentage of 
Foxp3+ T cells was increased in naïve, HES + Concanavalin (Con) A stimulated 
splenocyte cultures, compared to Con A only treated cultures. Con A is a T cell 
mitogen needed for Foxp3 induction, as this process requires TCR activation. The 
suppressive activity of these Foxp3+ cells was also assessed and was found to be 
comparable to natural Tregs. 
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The main difference with the Segura paper is that Grainger showed that HES, like 
transforming growth factor (TGF) β, induces Foxp3 without necessity for antigen 
presenting cells (APCs), by directly culturing Foxp3-CD4+ T cells in presence of 
HES. Knowing this, he tried to further characterise this TGFβ-like activity. Among 
other experiments, Grainger used a chemical inhibitor of the activin receptor-like 
kinase (ALK) 5 (SB431542) since the TGFβ signalling cascade depends on the 
heterodimerisation of TGFβRII with ALK5/TGFβRI. After a pre-treatment with this 
inhibitor, he added HES or rhTGFβ1 to CD4+ T cells and observed no increase in 
Foxp3 expression in the culture containing the inhibitor. This proved that the Foxp3 
inducing activity of the HES is dependent on the TGFβ receptor. Although this 
experiment was performed on T cells, the protocol could easily be adapted to DCs 
to assess if the TGFβ-like activity of HES plays a role in the dendritic cells 
immunomodulation. Some of Grainger’s findings were recently published in the 
Journal of Experimental Medicine [39]. 
1.7 Aims	  of	  the	  study	  
The goal of this project was to characterise the molecular interactions between the 
excretory/secretory products of H. polygyrus and dendritic cells of its murine host. 
We focussed our research on the TLR4-expressing classical DC subset derived 
from bone marrow in vitro, as there were several questions to tackle. 
• Which components of the HES are implicated in the interactions with the 
DCs? 
• Which molecules on the DC surface are targeted and what role do they play 
in the immunomodulatory process? 
• Which intra-cellular signalling pathway(s) HES is able to hijack in order to 
modify the gene expression profile of DCs? 
• Does the in vitro modulation of the dendritic cell activation profile correlate 
with an in vivo polarisation of the T helper response upon transfer of these 
DCs? 
On a long-term perspective, the answers to these questions will be a first step 
toward a better understanding of the global modulation of the mouse immune 
system by the parasite H. polygyrus. This understanding will be an indispensable 
means to achieve one or both of the two final goals, which are developing vaccines 
or therapies against human hookworm parasites and discover new 
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immunomodulatory molecules potentially able to limit autoimmune and allergic 
diseases. 
In our attempt to elucidate these questions, the previously described 
immunomodulatory properties of HES turned out to be extremely useful. On one 
hand, HES was modified, specifically depleted for one compound or fractionated 
and the DC cytokine production was used as a read-out to compare the different 
versions of the parasite product. On the other hand, the analysis of the HES anti-
inflammatory abilities on modified and DCs from knockout mice allowed to research 
the host side of the immunomodulatory process.  
Based on these four questions, this work was split into five parts, the first mainly 
dealing with the optimisation of the immunomodulation assay used by Segura and 
Grainger. The three chapters of the second part present our work on three different 
molecular signalling pathways that we thought could be involved in the regulation of 
the DC activation state. The third part focusses on our attempt to define molecular 
targets of interest in the HES, using size fractionation and characterising the effect 
of calreticulin, a HES component previously described as immunomodulatory [40]. 
The study of the physical interactions between HES and DCs, carried out with 
biotinylated HES, is described in the fourth part and, finally, the in vivo transfer 
experiments are summarized in the last chapter. 
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2 Materials and Methods 
2.1 Animals	  
C57BL/6, BALB/c and CD24-/- mice characterised by Nielsen et al. [41] were bred 
and maintained in a specific pathogen-free facility at the University of Edinburgh. 
Prof. Gordon Brown from the Aberdeen Fungal Group sent us bone marrow from 
129SV WT and 129SV Dectin1-/- mice. MyD88-/-, TRIF-/- and MyD88xTRIF-/- on a 
C57/BL6 background were given by David Gray’s laboratory, University of 
Edinburgh. 
2.2 General	  reagents	  
2.2.1 Complete	  RPMI	  
RPMI 1640 medium, containing HEPES, was supplemented with 2mM L-glutamine, 
100U/ml penicillin, 100µg/ml streptomycin and 5% foetal calf serum (FCS). All these 
compounds were purchased from Gibco. 
2.2.2 Bone	  marrow-­‐derived	  macrophage	  culture	  medium	  
Dubelcco’s Modified Eagle’s Medium (DMEM) was supplemented with 20% FCS 
(Gibco), 20% L929 conditioned medium (produced in the lab), 2mM L-glutamine 
(Gibco), 100U/ml penicillin (Gibco) and 100µg/ml streptomycin (Gibco). 
2.2.3 Hanks’	  buffer	  
Hanks’ balanced salt solution (HBSS) (Sigma) was supplemented with 2mM L-
glutamine (Gibco) and 50mg/ml FCS (Gibco) 
2.2.4 H.	  polygyrus	  culture	  solution	  
RPMI 1640 medium, containing HEPES, was supplemented with 2mM L-glutamine, 
100U/ml penicillin, 100µg/ml streptomycin, 10mg/ml sterile filtered glucose and 
0.1mg/ml Gentamicin. All these compounds were purchased from Gibco. 
2.2.5 0.06	  M	  carbonate	  buffer	  
45.3ml of Na2CO3 1 M (Sigma) and 18.2ml of Na2HCO3 1 M (Sigma) were added to 
936.5ml of distilled water. Then, the solution was adjusted to pH 9.6. 
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2.2.6 FACS	  buffer	  
For flow cytometry, we used phosphate buffer saline (PBS) containing 0.5% bovine 
serum albumin (BSA) and 0.1% sodium azide. 
2.2.7 Ex-­‐vivo	  media	  
X-vivo 15 serum free media (BioWhittaker) was supplemented with 2mM L-
glutamine, 100U/ml penicillin and 100µg/ml streptomycin. 
2.3 Triton	  X114-­‐mediated	  LPS	  depletion	  
500µl of recombinant H. polygyrus calreticulin (HpCRT) were incubated with 1% 
Triton X114 (Sigma) for 30 minutes at 4°C on a rotating windmill, then 10 minutes at 
37°C and centrifuged at 17000g for 15 minutes at room temperature. The aqueous 
top phase was then carefully harvested and the whole process was repeated two 
more times. After the last repeat, the aqueous phase was kept at 37°C for 5 minutes 
and spun a second time at same speed for 15 minutes. No lipid phase was then to 
see, but, for safety, the bottom 20µl were not harvested. This product was then 
referred to as LPS-depleted HpCRT. 
2.4 H.	  polygyrus	  life	  cycle	  maintenance	  
Heligmosomoides polygyrus bakeri was maintained in CBAxC57/BL6F1 mice 
infected with 500 larvae by gavage. After 14 days, the mice were killed and the 
whole intestines were removed and cut into three sections. The upper section, 
consisting of the first half of the small intestine, in which worms could be seen, was 
kept in Petri dishes filled with Hanks’ buffer at 37ºC whereas the caeca and colons 
were temporarily kept in empty Petri dishes. Upper sections were opened by cutting 
the gut lengthways with scissors. Worms were harvested by scraping the inside of 
the gut wall with a glass microscope slide and the intestinal walls were removed 
from the Petri dishes. The worm-containing suspension was then incubated in a 
muslin bag, which allows only motile worms to pass through. To do so, muslin bags 
were immersed in a Hanks’ buffer-filled funnel connected to a plastic tube. This 
device was kept in a 37ºC incubator for about 1 hour until all worms had reached 
the bottom of the tube. 
During this time, H. polygyrus eggs-containing faeces were extracted from the 
colons and caeca. Charcoal was mixed with faeces until reaching a sticky 
consistency and plated on 5cm diameter dampened filter papers placed in the 
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centre of Petri dishes. These dishes were then kept in plastic boxes with humid 
paper to avoid faeces to dry. Larvae could then be collected from these plates each 
week for about one month by lifting off the filter paper and washing the Petri dish 
with water. After 3 washes in water larvae were kept at 4ºC until infection of mice. 
After the hour of incubation, adult worms were collected by disconnecting the plastic 
tube from the funnel. Worms were washed 6 times in Hanks’ buffer and another 6 
times under sterile conditions in Hanks’ buffer supplemented with 100 U/ml penicillin 
and 100 µg/ml streptomycin (Pen/Strep). Then, the media was complemented with 
1mg/ml Gentamicin for 20 minutes before washing the worms another 6 times in 
Pen/Strep-containing Hanks’ buffer. Finally, worms were separated evenly into T25 
flasks filled with 15ml H. polygyrus culture medium. These flasks were then 
incubated for 3 weeks at 37ºC and the culture media was collected and replaced 
every 3 to 4 days. Pools of this media were then diafiltrated into PBS over a 3000 
MWCO Amicon membrane to derive H. polygyrus excretory/secretory products used 
in the following experiments. 
2.5 Cell	  isolation	  and	  culture	  
2.5.1 Bone	  marrow-­‐derived	  DC	  culture	  
Femurs and tibias were extracted from mice and kept in ethanol for 3 minutes. 
Then, bones were washed 5 times in PBS, under sterile conditions. Ends of each 
bone were cut with a sterile scalpel and bone marrow was flushed out using PBS 
and a 0.5mm needle. The suspension was then homogenised by repeated 
passages through a 0.8mm needle. Cells were counted and plated at 2x106 cells per 
bacteriological Petri dish in 10ml complete RPMI supplemented by 20ng/ml GM-
CSF (Peprotech) and incubated at 37ºC, 5% CO2 for 10 days. 10ml complete RPMI 
+ 20ng/ml GM-CSF were added to each plate at day 3 of culture. Then, the media 
was partially replaced at days 6 and 8 by removing 10ml of the culture media from 
the edge of the plate and adding 10ml fresh RPMI + 20ng/ml GM-CSF. Finally, cells 
were harvested on day 10 by carefully washing the plates with media. 
2.5.2 Bone	  marrow-­‐derived	  macrophage	  (BMDM)	  culture	  
To grow macrophages, cells recovered from bone marrow following the protocol 
described in the previous paragraph were re-suspended at 6x105 cells/ml in 
macrophage-colony stimulating factor (M-CSF)-containing BMDM culture media and 
10ml of this suspension were plated per bacteriological Petri dish. The plates were 
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incubated at 37ºC, 5% CO2 for 7 days and the media was replaced at day 4 by 
totally removing the exhausted media from the edge of the plate and carefully 
adding 10ml fresh BMDM culture media. On day 7, the culture media was again 
completely removed from the edge of the Petri dish. Then, the adherent cell 
population was carefully washed twice in 2ml warm PBS per plate. Next, 
macrophages were detached by incubating them for 10 minutes with 2.5ml per plate 
warm PBS, 3mM EDTA (Gibco), 10mM D-glucose (Sigma). Cells were then 
harvested with a Pasteur pipette and washed in 40ml warm PBS. Finally, they were 
re-suspended in DMEM containing 20% FCS, 2mM L-glutamine and Pen/Strep, 
counted and diluted at 106 cells/ml to be plated at 105 cells per well in the assays. 
2.5.3 Adoptive	  transfer	  of	  DCs	  
Day 10 BMDCs were incubated with 25µg/ml HES, 25µg/ml hiHES or 10µg/ml of 
heat-inactivated Propionibacterium acnes extract (Pa) (gift of Andrew MacDonald 
laboratory) or a combination of HES and Pa or hiHES and Pa in 6-well plates (2*106 
cells/ml in complete RPMI containing 5ng/ml GM-CSF). After 18 hours incubation at 
37ºC 5% CO2, cells were harvested and spun down at 400g. Supernatants were 
frozen for subsequent cytokine analysis, whereas cells were washed twice in PBS to 
remove the different antigens. Next, cells were re-suspended in PBS at 5*106 
cells/ml and then injected into mice intra-peritoneally (i.p.) (100µl cell suspension 
per mouse). Finally, the remaining cells were stained and analysed for activation 
markers by flow cytometry. 
2.5.4 Draining	  lymph	  nodes	  and	  splenocytes	  re-­‐stimulation	  
Seven days after the DC transfer, spleens and peritoneal draining lymph nodes 
were mashed through a 70µm nylon filter to create a single cell suspension in ex-
vivo media. After 4 minutes in red blood cell (RBC) lysis buffer (Sigma), splenocytes 
were washed in ex-vivo media, counted and plated in a 96-well plate at 2*106 
cells/well in a total volume of 200µl/well ex-vivo media. Lymph node suspensions 
were directly counted (without RBC lysis) and plated at 5*105 cells/well. Cells were 
re-stimulated with 2µg/ml anti-CD3 antibody (clone 145-2C11, Biolegend), 10µg/ml 
HES or 1µg/ml Pa or left in media. After 72 hours incubation, supernatant cytokines 
levels were measured by ELISA. 
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2.6 DCs	  activation	  assays	  
In order to assess the immunomodulatory effects of HES, Day 10 BMDCs were 
counted, diluted at 106 cells/ml and plated at 105 cells/well in 96-well plates. DCs 
were stimulated with different TLR ligands, hot alkali-treated zymosan (Invivogen) or 
the monoclonal anti-CD40 FGK45 antibody produced in the lab by James Hewitson 
as described previously [42]. LPS (Sigma) was used at a concentration of 1µg/ml, 
CpG (ODN 1826, Invivogen) at 10µg/ml, Pam3CSK4 (Invivogen) at 100ng/ml and 
R848 (Invivogen) at 1µg/ml. Depending on the assay, they were simultaneously 
treated with different concentrations of HES, HES fractions, hiHES or some 
recombinant proteins. To avoid any time dependent effect, all compounds were 
plated first and the cells were always added last. HES and hiHES were titrated 
between 0.05 µg/ml and 50 µg/ml. Heat-inactivated HES was produced by 
incubating HES at 95°C for 20 minutes. HES fractions were plated at 10µg/ml, 
based on an estimation of their stock concentration and the assumption that the 
HES proteins were evenly distributed amongst the fractions. Recombinant human 
TGFβI (rhTGFβ) (R&D Biosciences) was used at 0.5, 1 or 2ng/ml and LPS-depleted 
H. polygyrus calreticulin (HpCRT) between 1ng/ml and 10µg/ml. All these 
compounds were plated in 50µl/well complete RPMI, so that the total volume of 
each well reached 200µl. 
In the TGFβ experiments, few samples of HES were also pre-incubated for 30 
minutes with 10µg/ml of a pan-vertebrate anti-TGFβ antibody (clone 1D11). In 
addition, for some experiments, BMDCs were treated with monoclonal blocking 
antibodies for 30 minutes before the activation. Anti-Dectin-1 antibody (clone 
218820, R&D) was used at 3µg/ml, according to the datasheet. Anti-Dectin-2 (clone 
D2.11E4, AbD Serotec) was used at various concentrations between 2 and 
100µg/ml. 
For chemical inhibitions, BMDCs were pre-treated for 30 minutes with less than 
1/500 volume/volume DMSO containing or not the inhibitor. ALK5 was blocked with 
a final concentration of 5µM SB431542 (Tocris Bioscience). Spleen tyrosine kinase 
inhibitors ER 27319 maleate (Tocris Bioscience) and BAY 61-3606 (Santa Cruz 
Biotechnology) were titrated between 10nM and 10µM. PI3K was inhibited with 
10nM, 100nM or 1µM wortmannin (Calbiochem). 
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Finally, the plates were incubated for 18 hours at 37°C and 5% CO2, then spun at 
400g for 2 minutes. The supernatant was collected for cytokine detection and cells 
were stained for flow cytometry analysis. 
2.7 Detection	  of	  cytokines	  by	  ELISA	  
Enzyme-linked immunosorbent assay (ELISA) was used to detect levels of 
cytokines in the culture supernatants. ELISA plates (Immunoplate MaxiSorp, NUNC) 
were first coated with capture antibody at concentrations stated in Table 1 in 
carbonate buffer (50µl per well). The plates were then incubated overnight at 4°C. 
The next day, the plates were washed five times with TBST (TBS + 0.05% Tween) 
and then blocked with 200µl per well TBST + 10% FCS during two hours at 37°C. 
The plates were then washed another five times with TBST before adding standards 
and samples (50µl per well). Standards were made up in complete RPMI by serial 
doubling dilution from the top concentrations indicated in table 1. Again, plates were 
incubated at 4°C overnight. 
On the third day, plates were washed five times in TBST. Then, the biotinylated 
detection antibody was added at the appropriate concentration (see Table 1) in 
TBST + 5% FCS (50µl per well) and the plates were incubated for one hour at 37°C. 
After five additional washes in TBST, Extravidin alkaline phosphatase (AP) 
(1/10000) or Streptavidin-horseradish peroxidase (Strep-HRP) conjugate (1/1000) 
(both from Sigma) were added as developing enzymes in TBST + 5% FCS (50µl per 
well) and plates were incubated for another 45 minutes. Finally, plates were washed 
five times in TBST and two times in ultra pure water. Extravidin AP was revealed by 
50µl/well p-nitrophenyl phosphate (pNPP) substrate whereas 50µl/well 1:1 ABTS 
reagent (KPL) were used to develop Strep-HRP-coated wells. The plates were then 
incubated in the dark until colour appeared. Finally, the optical density (OD) of each 
well was measured at 405nm with a precision microplate reader (Molecular 
Devices). 
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 Capture Ab Conc. Top Standard 
Conc. 
Detection 
Ab Conc. 
Developing 
Enzyme 
IFN-γ  2 µg/ml 50 ng/ml 1 µg/ml Extrav. AP 
IL-4 2 µg/ml 8 ng/ml 1 µg/ml Extrav. AP 
IL-5 1 µg/ml 10 ng/ml 1 µg/ml Extrav. AP 
IL-6 2 µg/ml 25 ng/ml 0.5 µg/ml Extrav. AP 
IL-10 4 µg/ml 10 ng/ml 2 µg/ml Extrav. AP 
IL-12p40 2 µg/ml 50 ng/ml 0.5 µg/ml Extrav. AP 
IL-12p70 4 µg/ml 50 ng/ml 0.5 µg/ml Extrav. AP 
IL-13 2 µg/ml 10 ng/ml 0.5 µg/ml Extrav. AP 
IL-17 0.5 µg/ml 20 ng/ml 250 ng/ml Extrav. AP 
TNFα  0.8 µg/ml 4 ng/ml 150 ng/ml Strep-HRP 
     
 Capture Clone and Supplier 
Recombinant 
cytokine  
Detection Clone and 
Supplier 
IFN-γ  R46A2, in house BD XMG1.2, BD 
IL-4 11B11, in house BD BVD6-24G2, BD 
IL-5 TRFK5, BD BD TRFK4, BD 
IL-6 MP5-20F3, BD BD MP5-32C11, BD 
IL-10 JES5-2A5, BD BD SXC-1, BD 
IL-12p40 C15.6, BD R&D C17.8, BD 
IL-12p70 9A5, BD R&D C17.8, BD 
IL-13 38213, R&D R&D Polycl. rabbit IgG, Peprotech 
IL-17 TC11-18H10, BD R&D TC11-8H4.1, BD 
TNFα  Polycl. goat IgG, R&D BD Polycl. goat IgG, R&D 
	  
Table	  1	  –	  Technical	  specifications	  of	  ELISA	  antibodies	  BD	  stands	  for	  BD	  PharmingenTM,	  R&D	  stands	  for	  R&D	  Systems.	  
2.8 Biotinylated	  lectins	  ELISA	  
To detect glycans in the different HES fractions, ELISA plates (Immunoplate 
MaxiSorp, NUNC) were first coated with 1µg/ml total HES or the estimated 
equivalent protein amount of each HES fraction in 50µl/well carbonate buffer. After 
an overnight incubation at 4°C, plates were washed 5 times in TBST and blocked for 
2 hours at 37°C with 200µl/well TBST 0.5% casein (BDH Chemicals). After 5 
washes in TBST, the seven biotinylated lectins of the kit I from Vector Labs were 
diluted at 2µg/ml in TBST 5% FCS and 50µl/well were plated and incubated for 2 
hours at 37°C. Plates were then washed 5 times in TBST and Strep-HRP was 
added at 1/1000 in 50µl/well TBST 5% FCS for a 30 minutes incubation at room 
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temperature. Finally, plates were washed, developed and read as described in the 
previous section. 
2.9 Flow	  cytometry	  
A subset of cells from each culture was kept for flow cytometry analysis. Cells were 
first centrifuged at 400g for 5 minutes, then re-suspended in FACS buffer, spun 
again and blocked in 500µl/Eppendorf or 30µl/well in a 96-well plate rat IgG FcR 
block (1/40) for 5 minutes at 4°C. Then, cells were washed in FACS buffer, before 
staining them for 20 minutes at 4°C. A maximum of 2x106 cells were used for each 
stain. All fluorophore-attached antibodies (see table 2) were used at 1/200 dilution in 
200µl/Eppendorf or 20µl/well staining solution except for anti-Dectin-1 antibody that 
was used at 1/10 and MHCII-PerCP antibody that was used at 1/400. After the 
staining step, cells were washed twice in FACS buffer and directly flowed through 
the FACS analyser or fixed in 2% paraformaldehyde (PFA) for a later use. 
Target Colour Clone Company 
B220 PerCP RA3-6B2 Biolegend 
CD11b Pacific Blue M1/70 Biolegend 
CD11c APC N418 
 
Biolegend 
 
CD11c Pacific Blue N418 
 
Biolegend 
 
CD11c PE N418 
 
Biolegend 
 
CD24 PE-Cy7 M1/69 Biolegend 
 CD4 FITC GK1.5 
 
Biolegend 
 
CD40 FITC 3/23 
 
BD 
CD40 PE 3/23 
 
BD 
CD8 FITC 53-6.7 
 
Biolegend 
 
CD80 PE 16-10A1 
 
BD 
CD80 APC 16-10A1 
 
Biolegend 
 
CD86 PE GL-1 BD 
CD86 Alexa Fluor® 488 GL-1 Biolegend 
Dectin-1 APC 2A11 AbD Serotec 
F4/80 Alexa Fluor® 488 BM8 Caltag 
F4/80 PerCP-Cy5.5 BM8 Biolegend 
Gr-1 PerCP RB6-8C5 Biolegend 
MHC class II FITC M5/114.15.2 Biolegend 
 
MHC class II PerCP M5/114.15.2 Biolegend 
 Streptavidin APC Streptavidin Biolegend 
 	  
Table	  2	  –	  Technical	  specifications	  of	  flow	  cytometry	  antibodies	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For the biotinylated HES binding experiments, the same protocol was used, but 20µl 
of FACS buffer with or without biotinylated HES at final concentrations ranging from 
0.25 to 4 µg/ml were added to the cells during the main staining step. Then, a 
second staining step of 15 minutes at 4°C followed by two supplementary washes 
was performed to allow for streptavidin-biotin binding. 
Flow cytometry analyses were performed with a FACS Canto or a LSRII cytometer 
(BD Bioscience) and the FlowJo software (TriStar). 
2.10 Two	  dimensional	  electrophoresis	  
In a first step, proteins were separated by charge by isoelectric focusing (IEF), using 
the Ettan IPGphor II IEF System. To this end, 8µl IPG Buffer pH 3-10 (GE 
healthcare) and 50mg 1,4-dithioerythriol (DTE) (Fluka) were added to a 1ml aliquot 
of rehydration buffer (7 M urea (GDH), 2 M Thiourea (GDH), 4% CHAPS (Sigma) 
and trace of bromophenol blue (Sigma)). 25µl of each sample were then mixed with 
100µl of this solution and spread on an IEF strip holder. A 7 cm Immobiline™ 
DryStrip pH 3-10 (GE healthcare) was then loaded on the strip holder and toped 
with PlusOne DryStrip cover fluid (Amersham Bioscience). The holders were then 
placed on the Etan IPGphor II for isoeletric focusing. 
On the next day, IEF strips were equilibrated and the size separation was achieved 
by SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis). Each 
strip was first incubated on a rocker for 15 minutes with 2ml of strip equilibration 
solution (1.5 M Tris pH 8.8, 6 M urea, 30% glycerol, 2% SDS, and trace of 
bromophenol blue) supplemented with 20mg DTE followed by 15 minutes with 2ml 
strip equilibration solution supplemented with 80mg iodoacetamide (Sigma). Strips 
were then loaded on NuPAGE 4-12% Bis-Tris ZOOM gel (Invitrogen), topped with a 
hot 0.5% w/v agarose solution (in MES SDS running buffer (Invitrogen) with trace of 
bromophenol blue) and ran in MES SDS running buffer at 120V for one hour. 
2.11 Silver	  staining	  
To reveal the proteins on the 2D-gels, the Amersham Mass Spectrometry safe silver 
staining method was used. The gels were successively incubated for 30 minutes in 
fixation buffer (40% ethanol (Fisher Scientific), 10% glacial acetic acid (Fisher 
Scientific) in double-distilled water) and 30 minutes in sensitising buffer (30% 
ethanol, 5% w/v sodium thiosulphate (Sigma), 0.8 M sodium acetate (Sigma) in 
double-distilled water), then, washed three times 5 minutes in distilled water. They 
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were then stained in a 2.5% w/v silver nitrate (Sigma) solution (in double-distilled 
water) for 20 minutes in the dark and washed twice for one minute with double-
distilled water. Finally, the gels were incubated in developing buffer (200mM sodium 
carbonate (Sigma), 0.01% formaldehyde (Sigma) in double-distilled water) for about 
5 minutes until the apparition of clear dots. At that point, the reaction was stopped 
with 40mM EDTA-N2Na2.2H2O in double-distilled water. 
2.12 Western	  blot-­‐like	  detection	  of	  glycans	  
In order to detect glycans on the HES compounds, 2D-gels were transferred onto a 
nitrocellulose membrane (BioRad) for western blotting. To this end, a classical 
sandwich configuration was set up in a semi dry transfer apparatus and the device 
was run for 90 minutes at 35V in NuPAGE transfer buffer (Invitrogen). The 
nitrocellulose membrane was then blocked in TBST 0.5% BSA for one hour at room 
temperature on a rocker before an overnight incubation at 4°C with biotinylated 
concanavalin A diluted at 2µg/ml in TBST 0.5% BSA. On the next day, membranes 
were washed twice for 10 minutes in TBST and incubated one hour at room 
temperature with Strep-HRP diluted at 1/1000. After two additional 10 minutes 
washes in TBST, bound Con A was revealed by covering the membrane with the 
enzyme substrate (a 1:1 mix of ChemiGlow Luminol/Enhancer Solution and 
ChemiGlow Stable Peroxide Solution (Cell Biosciences)) for 5 minutes. The gels 
were then read on a GelDoc device (Alpha Innotech). 
2.13 Statistical	  analysis	  
Student’s T tests were performed with Prism 5.0c (Graphpad Software Inc.) to 
compare pairs of groups. Two-tailed P values smaller than 0.05 were considered 
significant. 
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3 Results 
3.1 In	  vitro	  immunomodulation	  of	  BMDCs	  by	  H.	  polygyrus	  bakeri	  ES	  
Before starting to ask how H. polygyrus is able to modify the behaviour of DCs as 
reported by Segura [37] and Grainger [39], we needed to choose the best protocol 
for growing our BMDCs in vitro and then make sure that the reported 
immunomodulation could be achieved. As this project is built on top of John 
Grainger’s work in the Maizels laboratory, it was logical to keep his protocol for 
growing BMDCs. However, his method takes ten days and, aiming for efficiency, we 
decided to compare it with a seven days protocol in which media were changed on 
days 3 and 6 and cells were harvested on day 7. First of all, we compared the 
outcome of the cell cultures after 7 or 10 days by flow cytometry, looking for their 
expression of CD11c, MHC class II, and contaminations of T cells (CD4 and CD8), 
B cells (B220) or granulocytes (Gr-1) which are all cell types that can be derived 
from bone marrow progenitors. We immediately noticed that the percentage of 
BMDCs was higher and the Gr-1 expressing population smaller after ten days of 
culture (Fig. 1). Moreover, a CD4 positive population was still present after 7 days, 
but had totally disappeared after 10 days of culture. This figure also shows that it is 
possible to reach about 90% of CD11c positive cells with the ten days protocol as 
opposed to only 60% after seven days. 
Regarding the co-activation markers, we determined that the naïve day 10 BMDCs 
express high levels of CD80, intermediate levels of CD86, but nearly no CD40 (Fig. 
2). All these markers as well as MHC class II were up-regulated upon LPS ligation, 
but the addition of HES in the culture medium reduced this augmentation in a dose-
dependent manner (Fig. 3), thus confirming Grainger’s data. During the whole 
project, the phenotype of BMDCs was checked for every single culture and, if DCs 
expressed abnormally high levels of CD40 and CD86, the culture was discarded. 
In addition, we had to optimise the assay used by Segura and Grainger and try to 
get the strongest HES immunomodulation, so that potential intermediate effects 
could be seen more clearly in future experiments. Therefore, we co-treated Day 7 
and Day 10 BMDCs with different TLR ligands, including LPS used by Grainger and 
CpG used by Segura, along with different HES concentrations and looked for the 
cytokine level modification in the culture supernatant 18 hours later. This timing, 
also chosen by Grainger, allows the DCs to reach their maximal production of IL-
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12p70 and TNFα [43], two cytokines that could be useful read-outs for our 
experiments. As expected, IL-12p70 showed the best signal to noise ratio with a 
very strong suppression induced by co-treatment with more than 5µg/ml HES (Fig. 
4). TNFα down-regulation was also efficient. IL-6 and IL-12p40 seemed to show a 
slight down-regulation with high doses of HES whereas IL-10 level stayed quite 
stable upon HES addition. Concerning TLR ligands, Pam3 did not induce IL-12p70 
and was therefore rejected. As CpG and LPS showed similar patterns, we chose to 
perform our next experiments with LPS for financial reasons, but also because the 
cytokines levels seemed more consistent amongst the triplicate wells. Finally, 
following these results, we decided to use HES at a concentration of 10ug/ml in the 
next assays to ensure the most efficient immunomodulation, while sparing this 
precious product. 
The comparison of the two culture protocols revealed that the IL-6 and IL-12p70 
immunomodulation was conserved, but Day 7 cells did not change their IL-12p40 
production in response to HES treatment and IL-10 seemed to be weakly down-
regulated by HES in the Day 7 setting. More importantly, LPS and CpG induced 
around 6 times more IL-12p70 on Day 10 DCs than on Day 7 DCs. This, along with 
the phenotype differences described earlier, convinced us to retain the Day 10 
protocol for the rest of the project. 
To complement Grainger’s study on heat-inactivated HES, we decided to treat LPS 
activated BMDCs with a titration of this product. The goal was to confirm that hiHES 
couldn’t down-regulate the inflammatory cytokines production of DCs. Surprisingly, 
the level of IL-12p70 was in fact lower in the LPS/hiHES co-treated group than in the 
LPS treated group, but this effect was independent of the hiHES concentration (Fig. 
5). This result clearly shows that the immunomodulatory properties of HES are heat-
labile, but opens the question of a parasite effect due to the boiling procedure that 
could for example modify the interactions of some HES components with the plastic 
walls of the Eppendorf tubes or even induce the release of some molecules of the 
tube in the solution. To assess the effect of the boiling procedure, we treated LPS 
pulsed DCs with boiled PBS and noticed the same kind of intermediate cytokines 
levels (Fig. 6). Thus, even if this result seems to confirm that hiHES by itself does 
not change the cytokine production, it also indicates that the heating procedure was 
not optimal. Nevertheless, in regards of all the data collected during the project, 
boiling HES seems to disrupt dramatically its ability to down-regulate inflammatory 
cytokines production, suggesting that heat-labile components, like proteins, are 
crucial in this process. 
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Another issue was the timing of the addition of HES in the medium relatively to the 
TLR ligation. In his studies, Grainger treated the DCs with LPS and HES 
simultaneously, whereas Segura pre-treated the cells with HES for 2 hours before 
the addition of CpG. As both settings seemed to work, we decided to further 
investigate the ability of HES to down-regulate the inflammatory cytokine production 
even after the TLR ligation. Surprisingly, HES turned out to be even more potent 
than expected, suppressing nearly totally IL-12p70 production and still down-
regulating other inflammatory cytokines levels when added to the culture medium up 
to 8 hours after LPS (Fig. 7). These results also confirmed that a simultaneous 
treatment with HES and the TLR ligand was perfectly efficient on top of being the 
simplest way of setting up the assay. 
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Figure	  1	  –	  Comparative	  flow	  cytometry	  analysis	  of	  day	  7	  and	  day	  10	  naïve	  BMDCs.	  Naïve	  BMDCs	   grown	   either	   7	   or	   10	   days	   in	   complete	  RPMI	   +	   20ng/ml	  GM-­‐CSF	  were	  stained	  for	  their	  surface	  expression	  of	  CD11c,	  MHC	  class	   II,	  CD4,	  CD8,	  B220	  and	  Gr-­‐1.	  Using	   the	   forward	   and	   side	   scatter,	   dead	   cells	   were	   gated	   out.	   Positive	   gates	   were	  chosen	   in	   accordance	   with	   the	   single	   stains	   and	   unstained	   histograms	   for	   each	  fluorophore.	  
	  
 
Figure	  2	  –	  Example	  of	  a	  flow	  cytometry	  analysis	  of	  day	  10	  naïve	  BMDCs.	  As	  for	  figure	  1,	  DCs	  were	  stained	  and	  live	  cells	  were	  gated	  for	  their	  surface	  expression	  of	  CD11c,	  MHC	  class	  II,	  CD40,	  CD80	  and	  CD86.	  Representative	  plots	  of	  the	  majority	  of	  the	  cultures	  are	  displayed.	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Figure	   3	   –	   HES	   limits	   the	   up-­regulation	   of	   co-­stimulatory	   surface	   markers	   in	  
response	  to	  TLR4	  ligation.	  Day	  10	  BMDCs	  were	  either	  stimulated	  for	  18	  hours	  with	  10µg/ml	  HES	  or	  1µg/ml	  LPS	  with	  or	  without	  HES	  (0.1µg/ml,	  1µg/ml	  or	  10µg/ml)	  or	  kept	  un-­‐stimulated	  during	  that	  time.	  DCs	  were	  then	  stained	  for	  CD11c,	  MHC	  class	  II,	  CD40,	  CD80	  and	  CD86	  and	  gated	  for	  live	  and	  CD11c	  positive	  cells.	  The	  geometric	  mean	  of	  the	  fluorescence	  intensity	  was	  then	   calculated	   for	   each	   marker.	   Representative	   plots	   of	   several	   experiments	   are	  displayed.	  In	  this	  experiment,	  single	  wells	  were	  analysed	  and	  no	  statistics	  are	  therefore	  available.	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Figure	   4	   Part	   1	   –	   HES	   down-­regulates	   IL-­6,	   IL-­12p40,	   IL-­12p70	   and	   TNFα 	  
production	  in	  a	  dose-­dependent	  manner	  in	  response	  to	  TLR	  ligation.	  Day	  7	  or	  Day	  10	  BMDCs	  were	  stimulated	  for	  18	  hours	  with	  one	  or	  no	  TLR	  ligand	  and	  different	   concentrations	   of	   HES	   ranging	   from	   0	   to	   50	   µg/ml.	   Concentrations	   of	  cytokines	  in	  the	  supernatants	  were	  then	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  standard	   error	   of	   the	  mean	   (SEM)	   of	   triplicate	   wells	   from	   the	   same	   BMDCs	   culture.	  Statistics	  shown	  compare	  to	  the	  cytokine	  level	  of	  LPS-­‐treated	  DCs	  with	  the	  production	  of	   DCs	   treated	   with	   LPS	   and	   10µg/ml	   HES.	   Results	   of	   Student’s	   t	   test:	   *P<0.05,	  **P<0.01,	  ***P<0.001.	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Figure	   4	   Part	   2	   –	   HES	   down-­regulates	   IL-­6,	   IL-­12p40,	   IL-­12p70	   and	   TNFα 	  
production	  in	  a	  dose-­dependent	  manner	  in	  response	  to	  TLR	  ligation.	  Day	  7	  or	  Day	  10	  BMDCs	  were	  stimulated	  for	  18	  hours	  with	  one	  or	  no	  TLR	  ligand	  and	  different	   concentrations	   of	   HES	   ranging	   from	   0	   to	   50	   µg/ml.	   Concentrations	   of	  cytokines	  in	  the	  supernatants	  were	  then	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  standard	   error	   of	   the	  mean	   (SEM)	   of	   triplicate	   wells	   from	   the	   same	   BMDCs	   culture.	  Statistics	  shown	  compare	  to	  the	  cytokine	  level	  of	  LPS-­‐treated	  DCs	  with	  the	  production	  of	   DCs	   treated	   with	   LPS	   and	   10µg/ml	   HES.	   Results	   of	   Student’s	   t	   test:	   *P<0.05,	  **P<0.01,	  ***P<0.001.	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Figure	  5	   –	  Heat-­inactivated	  HES	   shows	  a	  dose-­independent	   intermediate	  down-­
regulation	  of	  IL-­12p70	  production.	  Day	   7	   or	   Day	   10	   BMDCs	   were	   stimulated	   for	   18	   hours	   with	   1	   µg/ml	   LPS	   and	   one	  concentration	   of	   HES	   or	   heat-­‐inactivated	   HES	   (HES	   boiled	   at	   95°C	   for	   20	   minutes)	  ranging	   from	  0.05	   to	   50µg/ml.	   IL-­‐12p70	   concentration	   in	   the	   supernatants	  was	   then	  measured	   by	   ELISA.	   The	   horizontal	   line	   shows	   the	   average	   value	   of	   triplicate	   wells	  stimulated	   with	   LPS	   only.	   Error	   bars	   represent	   the	   SEM	   of	   triplicate	   wells	   from	   the	  same	   BMDCs	   culture.	   Results	   of	   Student’s	   t	   test:	   non	   significant	   (ns)	   P>0.05,	  ***P<0.001.	  
 
Figure	   6	   –	   The	   down-­regulation	   of	   LPS-­induced	   IL-­6	   by	   hiHES	   is	   similar	   to	   the	  
effect	  of	  boiled	  PBS.	  BMDCs	  were	  stimulated	   for	  18	  hours	  with	  a	  combination	  of	  PBS,	  boiled	  PBS	  (B	  PBS),	  1µg/ml	  LPS,	  10µg/ml	  HES	  or	  10µg/ml	  hiHES.	  IL-­‐6	  and	  IL-­‐12p70	  concentrations	  in	  the	  supernatant	  were	  measured	  by	  ELISA,	  but	  there	  were	  no	  detectable	  levels	  of	  IL-­‐12p70	  in	   this	   experiment.	   Error	   bars	   represent	   the	   SEM	   of	   triplicate	   wells	   from	   the	   same	  BMDCs	   culture.	   Results	   of	   Student’s	   t	   test:	   non	   significant	   (ns)	   P>0.05,	   *P<0.05,	  **P<0.01.	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Figure	  7	  –	  HES	  is	  still	  able	  to	  down-­regulate	  inflammatory	  cytokines	  up	  to	  8	  hours	  
after	  TLR4	  ligation.	  BMDCs	   were	   stimulated	   either	   with	   10µg/ml	   HES	   or	   with	   1µg/ml	   LPS.	   After	   30	  minutes,	   1	   hour,	   2,4,6	   or	   8	   hours,	   10µg/ml	   HES	   were	   added	   to	   LPS-­‐stimulated	   DCs.	  Cytokines	   levels	   were	   measured	   by	   ELISA	   in	   the	   supernatants	   after	   18	   hours	   of	  incubation.	   Error	   bars	   represent	   the	   SEM	   of	   triplicate	   wells	   from	   the	   same	   BMDCs	  culture.	   The	   horizontal	   bars	   indicate	   that	   the	   cytokine	   concentration	   was	   below	   the	  detection	   limit.	   L	   stands	   for	   LPS,	   H	   for	   HES,	   sim.	   for	   simultaneously,	   n.d.	   for	   not	  detected.	  Statistics	  shown	  compare	  the	  cytokine	  levels	  of	  the	  corresponding	  group	  with	  the	  LPS-­‐treated	  group.	  Results	  of	  Student’s	  t	  test:	  non	  significant	  (ns)	  P>0.05,	  **P<0.01,	  ***P<0.001.	  Data	  are	  representative	  of	  two	  similar	  experiments.	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3.2 HES	  can	  skew	  DCs	  responses	  independently	  of	  the	  TGFβ	  pathway	  
Following Grainger’s discovery of the TGFβ-like activity of HES in his experiments 
on CD4+ T cells [39], we decided to test if this pathway was also relevant for the 
observed effects on DCs. First, we checked that the HES was not contaminated with 
some residual mammalian TGFβ from the murine host. BMDCs were co-treated with 
LPS and neat HES or HES pre-treated for 30 minutes with a pan-vertebrate anti-
TGFβ antibody. No significant differences in IL-6 production, but a slight up-
regulation of IL-12p70 were seen between the two groups (Fig. 8) arguing against 
the contamination hypothesis. The efficacy of the depletion was assessed by 
treating DCs with LPS and a physiological concentration of 2ng/ml recombinant 
human TGFβ (rhTGFβ) in the presence or absence of the anti-vertebrate TGFβ 
antibody. This revealed that rhTGFβ is not able to limit the cytokine response to 
LPS. The addition of the anti-TGFβ antibody further increased the cytokine 
production, suggesting that the TGFβ depletion was efficient. 
Knowing that there was no contamination of HES with TGFβ from an external 
source, but aware that rhTGFβ had an effect on DCs cytokine production, we further 
assessed the immunomodulatory properties of the rhTGFβ. Although DCs co-
treated with LPS and TGFβ showed lower levels of inflammatory cytokines than the 
cells treated with LPS only, this down-regulation was not dose-dependent and DCs 
pre-treated for 30 minutes with the ALK5 inhibitor SB431542 produced similar levels 
of cytokine upon LPS/rhTGFβ co-stimulation (Fig. 9). These results prove that the 
activation of the TGFβ receptor on DCs is not sufficient to achieve the strong 
immunomodulation showed by HES. They also suggest that the TGFβ-like activity of 
HES discovered by John Grainger is unlikely to be part of the mechanism by which 
HES modifies the behaviour of DCs. 
To confirm this, we compared the levels of cytokines produced upon LPS only or 
LPS and HES stimulation on BMDCs pre-treated for 30 minutes with DMSO or the 
ALK5 inhibitor SB431542. Again, the two groups showed the same ability to down-
regulate the LPS-induced cytokine production (Fig. 10). Together these results 
suggest that the HES immunomodulation of GM-CSF-grown BMDCs is independent 
of the TGFβ pathway. However, the possibility remains that the ALK5 inhibition was 
not successful and our statement should therefore be confirmed with an experiment 
on TGFβ receptor-deficient DCs. 
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Figure	  8	  –	  HES	  anti-­inflammatory	  properties	  are	  not	  due	  to	  a	  contamination	  with	  
mammalian	  TGFβ .	  Some	  HES	  was	   incubated	  for	  30	  minutes	  with	  10µg/ml	  of	  a	  pan-­‐vertebrate	  anti-­‐TGFβ	  antibody	   to	   deplete	   it	   from	   any	   possible	   murine	   TGFβ.	   DCs	   were	   stimulated	   for	   18	  hours	   with,	   1µg/ml	   LPS,	   or	   a	   combination	   of	   LPS	   and	   10µg/ml	   neat	   HES,	   TGBβ-­‐depleted	  HES	  or	  2ng/ml	  recombinant	  human	  TGFβ	  (rhTGFβ)	  in	  presence	  or	  absence	  of	  anti-­‐TGFβ	   antibody.	   Cytokines	   levels	   in	   the	   supernatants	   were	   measured	   by	   ELISA.	  Error	  bars	  represent	  the	  SEM	  of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  Results	  of	  Student’s	  t	  test:	  non	  significant	  (ns)	  P>0.05,	  *P<0.05,	  **P<0.01,	  ***P<0.001.	  Data	  are	  representative	  of	  two	  similar	  experiments.	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Figure	  9	   –	  The	   anti-­inflammatory	   effect	   of	   recombinant	   human	  TGFβ 	   on	  DCs	   is	  
not	  dose-­dependent	  and	  does	  not	  rely	  on	  the	  TGFβ 	  receptor.	  BMDCs	   were	   stimulated	   with	   1µg/ml	   LPS	   and	   either	   10µg/ml	   HES	   or	   different	  physiological	   concentrations	   of	   rhTGFβ	   (0.5ng/ml,	   1ng/ml,	   2ng/ml).	   Some	   BMDCs	  were	   incubated	   for	   30	   minutes	   with	   5µM	   SB431542	   beforehand	   to	   block	   the	  dimerisation	  of	   the	  TGFβ	   receptor	  and	   then	   stimulated	  with	  1µg/ml	  LPS	  and	  2ng/ml	  rhTGFβ.	  After	  18	  hours	   the	  supernatant	  were	  collected	  and	   the	  cytokines	   levels	  were	  measured	   by	   ELISA.	   Error	   bars	   represent	   the	   SEM	   of	   triplicate	   wells	   from	   the	   same	  BMDCs	   culture.	   Results	   of	   Student’s	   t	   test:	   non	   significant	   (ns)	   P>0.05,	   *P<0.05,	  ***P<0.001.	  Data	  are	  representative	  of	  two	  similar	  experiments.	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Figure	  10	  –	  HES	  immunomodulation	  of	  DCs	  is	  independent	  of	  the	  TGFβ 	  receptor.	  BMDCs	  were	   incubated	   for	   30	  min	  with	   5µM	  SB431542	   or	   the	   equivalent	   volume	   of	  DMSO.	   Then,	   they	   were	   stimulated	   for	   18	   hours	   with	   10µg/ml	   HES,	   1µg/ml	   LPS	   or	  both.	   Cytokines	   levels	   in	   the	   supernatants	   were	   measured	   by	   ELISA.	   Error	   bars	  represent	  the	  SEM	  of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  The	  horizontal	  bars	  indicate	   that	   the	   cytokine	   concentration	   was	   below	   the	   detection	   limit.	   Results	   of	  Student’s	   t	   test:	   **P<0.01,	   ***P<0.001.	   Data	   are	   representative	   of	   two	   similar	  experiments.	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3.3 HES	  in	  vitro	  immunomodulation	  of	  DCs	  is	  independent	  of	  Dectin-­‐
1,	  Dectin-­‐2,	  and	  the	  Spleen	  tyrosine	  kinase	  pathway	  
Amongst all the C-type lectin receptors expressed by DCs (listed in this review [44]), 
we decided to assess the role of Dectin-1 and Dectin-2. Dectin-1 was targeted 
following work going on in Andrew MacDonald’s laboratory in our institute, showing 
that this receptor was up-regulated on DCs following stimulation with Schistosoma 
egg antigen (SEA), another helminth product. This receptor was also shown to 
modulate the DC cytokine production in response to fungal PAMPs [45]. First, we 
checked that our DCs were expressing Dectin-1 by flow cytometry (data not shown). 
Then, since a blocking antibody was available in the lab, we performed a preliminary 
experiment and pre-treated DCs with 3µg/ml monoclonal anti-Dectin-1 antibody for 
30 minutes and we compared the ability of HES to down-regulate LPS-induced 
cytokines on untreated DCs versus Dectin-1 blocked DCs. No difference could be 
spotted (Fig. 11). As the blocking efficiency of the antibody was difficult to check and 
thanks to the Gordon Brown laboratory in Aberdeen, we were able to perform one 
immunomodulation assay on Dectin-1-/- BMDCs. As suggested by the preliminary 
experiment, HES had the same effect on the Dectin-1-/- cells and their wild type 
counter-part (SV 129 strain). Unfortunately, IL-12p70 was not measurable in this 
experiment, but the perfect matching of the two IL-6 titration curves (Fig. 12) 
confirmed the results of the Dectin-1 blocking experiment and proved that HES does 
not require this receptor to modulate DC activation. 
The second CLR, we were interested in was Dectin-2. This receptor had already 
been shown to bind SEA and to mediate the activation of the Nlrp3 inflammasome 
pathway upon ligation of this helminth product [31]. Unfortunately, in this case we 
were unable to obtain knockout mice. Therefore, we could only try to block Dectin-2 
with an antibody. In a first experiment, we treated BMDCs for 30 minutes with 2, 5 or 
10µg/ml anti-Dectin-2 antibody already described to be efficient at 10µg/ml [46]. 
Then, we treated the DCs with LPS, HES or both. DCs treated with the blocking 
antibody displayed similar inflammatory cytokines levels to the untreated cells with 
three exceptions. IL-12p70 was not detectable for the 2 and 5µg/ml anti-Dectin-2 
treated groups, but the levels were so close to the detection limit that this results is 
possibly an artefact. The other exception is the 10µg/ml anti-Dectin-2 treated group, 
which showed a partial recovery of the TNFα level (Fig. 13A). To assess if this effect 
was real, we repeated the experiment with higher antibody levels (Fig. 13B). This 
second experiment showed that even at 50µg/ml the monoclonal anti-Dectin-2 
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antibody was unable to reverse HES effect. At 100µg/ml, the cytokine down-
regulation was even enhanced, but at this concentration we cannot exclude that the 
antibody affected other molecules on the DCs via non-specific interactions. Thus, 
assuming that the blockage was efficient, HES does not interact with DCs through 
Dectin-2. 
Finally, to assess more broadly the role of CLRs in the HES immunomodulation of 
DCs, but also to confirm the Dectin-2 result, which depends on the efficiency of the 
blocking antibody, we blocked the downstream signal transducer Syk. Two different 
chemical inhibitors were used. ER-27319 was reported to block Syk binding to 
phosphorylated FcγRI ITAMs [47] and should therefore block the signalling through 
CLRs that interact with this chain, like Dectin-2 or Mincle. BAY 61-3606 acts more 
downstream by blocking the Syk-mediated phosphorylation of the inhibitor of κB 
(IκB) and therefore the translocation of NF-κB into the nucleus and the subsequent 
cytokine production [48, 49] (See Appendix Fig. S 9). This inhibitor should therefore 
block any Syk-mediated activation of the cell. 
First, we checked that the inhibitors were acting as expected. We stimulated 
BMDCs with hot alkali-treated zymosan that binds Dectin-1, but not its other usual 
receptor TLR2. This allowed us to bypass the TLR pathway and specifically study 
the Syk pathway. As expected, ER-27319 was unable to limit IL-6, IL-10 and TNFα 
production upon zymosan stimulation except for the highest dose for which we 
cannot exclude non-specific effects. This is logical, as Dectin-1 does not signal 
through the FcγRI chain. On the other hand, BAY 61-3606 inhibited those cytokines 
in a dose-dependent manner (Fig. 14). Once again IL-12p70 was below the 
detection threshold. 
Then, we compared the ability of HES to down-regulate the LPS-induced cytokine 
production of DMSO-, ER-27319- or BAY 61-3606-treated BMDCs (Fig. 15). The 
results of this experiment are quite unique in this project, as the expression of IL-6, 
IL-12p70 and TNFα were most of the time highly correlated. This is not the case 
here and we can see some cytokine specific effects. For example, BAY 61-3606 
reduces IL-6 and IL-12p70 in response to LPS indicating that this inhibitor may also 
partially block Syk-independent IκB phosphorylation or maybe that Syk also 
participates in the NF-κB activation process upon LPS ligation. Surprisingly, TNFα 
shows the exact opposite effect. Another striking effect is the huge up-regulation of 
the IL-12p70 response to LPS by the ER-27319 treatment. This could suggest that a 
negative feedback mechanism responsible for the regulation of IL-12p70 levels is 
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dependent on the FcγRI ITAM phosphorylation. All together these results reveal an 
intrinsic problem of this experimental setup based on two different signalling 
pathways. We do not know, for example if LPS interacts with CLRs, as the results 
on figure 11 could suggest it, or if other receptors are interacting with the FCγRI 
chain in response to LPS. The number of variables was certainly too high to allow a 
clear understanding of the outcome. Thus, it could be a better idea to assess Syk 
implication, by looking at its phosphorylation state upon HES treatment in a future 
work. 
Nevertheless, the effect we were looking for, that is a recovery of the cytokine 
production upon LPS/HES co-treatment is totally absent, suggesting, along with the 
Dectin-1 and Dectin-2 experiments, that HES does not need the Syk pathway to 
modulate the DCs. However, this statement needs further studies to be confirmed. 
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Figure	  11	  –	  HES	   can	   still	  modulate	   the	   cytokine	   response	   to	  LPS	  after	   antibody	  
blocking	  of	  Dectin-­1.	  BMDCs	  were	   incubated	  30	  minutes	  with	  or	  without	  3µg/ml	  monoclonal	  anti-­‐Dectin-­‐1	  antibody	  and	  then	  stimulated	  for	  18	  hours	  with	  1µg/ml	  LPS	  in	  presence	  or	  absence	  of	  1µg/ml	  HES.	  Cytokines	  levels	  in	  the	  supernatants	  were	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  SEM	  of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  
 
Figure	  12	  –	  Dectin-­1-­/-­	  BMDCs	  display	  the	  same	  HES	  immunomodulation	  pattern	  
as	  the	  corresponding	  wild	  type	  DCs.	  BMDCs	  were	  derived	   from	  a	  Dectin-­‐1-­‐/-­‐	  mouse	  and	   its	  corresponding	  wild	   type	  strain	  (129	  SV).	  DCs	  were	   then	  stimulated	  with	  1µg/ml	  LPS	  and	  different	   concentrations	  of	  HES,	   ranging	   from	   0.05	   to	   50µg/ml	   or	   with	   only	   10µg/ml	   HES.	   IL-­‐6	   levels	   were	  measured	  by	  ELISA	  in	  the	  supernatants	  after	  18	  hours	  incubation.	  In	  this	  experiment,	  IL-­‐12p70	   levels	   were	   below	   the	   detection	   limit.	   Error	   bars	   represent	   the	   SEM	   of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  Statistics	  shown	  compare	  the	  LPS	  versus	  LPS+HES	  treatments	  for	  each	  strain.	  Results	  of	  Student’s	  t	  test:	  **P<0.01,	  ***P<0.001.	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Figure	  13	   –	  Dectin-­2	   antibody	  blockage	  does	  not	   alter	  HES	   immunomodulatory	  
properties.	  BMDCs	   were	   pre-­‐treated	   or	   not	   with	   different	   concentrations	   of	   a	   monoclonal	   anti-­‐Dectin-­‐2	  antibody	  (αD2)	  for	  30	  minutes.	  Concentrations	  in	  brackets	  are	  in	  µg/ml.	  Then,	  they	  were	   stimulated	  with	   1µg/ml	   LPS,	   10µg/ml	  HES	   or	   both	   (L+H).	   After	   18	   hours,	  cytokines	  levels	  in	  the	  supernatants	  were	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  SEM	  of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  The	  horizontal	  bars	  indicate	  that	  the	  cytokine	  concentration	  was	  below	  the	  detection	  limit	  (n.d.	  stands	  for	  not	  detected).	  Panels	  A	  and	  B	  present	  two	  different	  experiments.	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Figure	   14	   –	   The	   Syk	   inhibitor	   BAY	   61-­3606,	   but	   not	   ER-­27319	   is	   able	   to	   block	  
cytokine	  production	  upon	  Dectin-­1	  ligation.	  BMDCs	  were	  pre-­‐treated	  for	  30	  minutes	  with	  different	  doses	  ER-­‐27319,	  BAY	  61-­‐3606	  or	  an	  equivalent	  volume	  of	  DMSO.	  DCs	  were	  then	  stimulated	  with	  100µg/ml	  hot	  alkali	  treated	   zymosan	   (Z)	   that	   specifically	  binds	   to	  Dectin-­‐1	  but	  not	  TLR2.	  After	  18	  hours,	  cytokines	  levels	  in	  the	  supernatants	  were	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  SEM	  of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  The	  horizontal	  bars	  indicate	  that	  the	  cytokine	  concentration	  was	  below	  the	  detection	  limit	  (n.d.	  stands	  for	  not	  detected).	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Figure	   15	   –	   Syk	   inhibitors	   are	   unable	   to	   restore	   inflammatory	   cytokines	   levels	  
upon	  LPS/HES	  co-­stimulation.	  BMDCs	   were	   incubated	   for	   30	   minutes	   with	   1µM	   ER-­‐27319,	   1µM	   BAY	   61-­‐3606,	   an	  equivalent	  volume	  of	  DMSO	  or	  not	  treated	  at	  all	  to	  check	  for	  any	  DMSO	  induced	  effect.	  DCs	   were	   then	   stimulated	   with	   1µg/ml	   LPS,	   10	   µg/ml	   HES	   or	   both.	   After	   18	   hours,	  cytokines	  levels	  in	  the	  supernatants	  were	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  SEM	  of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  The	  horizontal	  bars	  indicate	  that	  the	  cytokine	  concentration	  was	  below	  the	  detection	  limit	  (n.d.	  stands	  for	  not	  detected).	  Results	  of	  Student’s	  t	  test:	  non	  significant	  (ns)	  P>0.05,	  **P<0.01,	  ***P<0.001.	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3.4 HES	  in	  vitro	  immunomodulation	  of	  DCs	  is	  independent	  of	  the	  TLR	  
and	  PI3K	  pathways	  
Although Segura et al. [37] showed that HES is still able to down-regulate IL-12p70 
production of TLR2-/- and TLR4-/- DCs, we decided to further study the pathway by 
measuring the cytokine response of MyD88 and TRIF deficient DCs. This allows 
assessing the role of all TLR ligands in a few experiments, as all of them are 
dependent on one or both of these adaptors to transmit the ligation signal. 
Moreover, even though retracted, the recent discovery by Puneet et al. [25] that the 
anti-inflammatory effects of ES-62, were due to its ability to induce the 
autophagosomal degradation of MyD88 suggest that these adapter molecules could 
be crucial targets for HES. In addition, based on a few papers [21, 23, 24, 26] 
suggesting that PI3K plays a regulatory role in the response to TLR ligation, we also 
investigated the response of PI3K-inhibited BMDCs to LPS and HES. This study of 
a lower level of signalling is also interesting since the PI3K/Akt/mTOR pathway was 
suggested to modulate both MAPK and NF-κB pathways in human monocytes [50]. 
In the first place, we treated BMDCs for 30 minutes with different concentrations of 
wortmannin, a common PI3K inhibitor. These DCs were then stimulated with LPS in 
the presence or absence of HES. At low and medium dose, wortmannin induced the 
up-regulation of IL-12p40 and p70 in response to LPS. On the contrary, at a high 
dose, PI3K inhibition led to a diminution of all measured cytokines, but TNFα (Fig. 
16). This could seem to contradict the previously cited papers, but, even though IL-
12 levels were lower when the cells were pre-treated with 1µM wortmannin rather 
than 10 or 100nM, they were still higher than the DMSO-treated DCs. Moreover, the 
increase of the wortmannin dose also tended to inhibit the IL-10 production, 
supporting the idea that the PI3K pathway plays an anti-inflammatory role in the 
setting of BMDCs activation by TLR ligation. Unfortunately, this effect turned out to 
be non significant. When looking at the LPS and HES co-treated group, we can see 
that, with the exception of TNFα, the wortmannin treatment does not induce a 
recovery of the inflammatory cytokine levels. TNFα levels were increased upon 
100nM or 1µM wortmannin pre-treatment, but they stayed below the corresponding 
values of the LPS-treated group. So, these results suggest that the HES 
immunomodulation of DCs is independent of the PI3K pathway. 
Second, we wanted to study the role of MyD88 and TRIF. To this end, we stimulated 
DCs derived from MyD88-/-, TRIF-/- or wild type bone marrow with four different TLR 
ligands and different concentrations of HES. As TLR4 can signal through both 
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MyD88- and TRIF-dependent pathways, the stimulation with LPS allows measuring 
the immunomodulatory effects of HES in the absence of one of these molecules, as 
the other intact pathway will still induce some cytokine production. Stimulation with 
CpG, Pam3 and R848 were used to assess the reproducibility of the results on a 
broader range of TLRs and check that the MyD88-dependent TLR9, TLR1/2 and 
TLR7/8 were unable to induce an inflammatory response in the MyD88 deficient cell 
lines. Their response was expected to be unaltered in TRIF-/- mice. 
As expected, MyD88-/- DCs did not produce any IL-6 upon CpG, Pam3 or R848 
stimulation (Fig. 17). Very low levels of this cytokine were still detectable after LPS 
activation showing that MyD88 is crucial for IL-6 production upon TLR4 ligation, 
even if the TRIF pathway was still functional. The TNFα levels were less affected 
although MyD88-/- DCs produced about four times less TNFα than wild type DCs 
upon LPS ligation. When stimulated with the other TLR ligands, the TNFα 
production by MyD88-/- DCs was similar to the levels induced by the non-stimulated 
control. CpG and Pam3 stimulation induced similar levels of IL-6 and TNFα in both 
wild type and TRIF-/- groups, but surprisingly, the production of these cytokines was 
diminished in TRIF-/- upon R848 stimulation suggesting a potential role for TRIF in 
the response to R848. More logically, the IL-6 levels reduction was strong upon LPS 
ligation as TLR4 also signals through the TRIF pathway. 
More importantly, every condition displayed the same dose-dependent cytokine 
down-regulation in response to HES co-treatment. Even LPS induced IL-6 produced 
by MyD88-/- BMDCs was reduced from 2.3ng/ml without HES to 1ng/ml with 10µg/ml 
HES. These results provide strong evidence that the HES modulation of DCs is 
independent of the TLR pathway. Moreover, they are supported by the flow 
cytometry analysis of co-stimulatory markers expressed on DCs after 18 hours 
stimulation (See Appendix Fig. S 1 and S 2). 
Nevertheless, it was still possible that HES acted redundantly through both MyD88 
and TRIF pathways. Thus, to rule out this hypothesis, we decided to performe an 
experiment on MyD88/TRIF double knockout BMDCs. In this setup LPS is useless 
for cell stimulation. Therefore, we tried to activate DCs through a CD40 ligation, as 
this had already been described to up-regulate co-stimulatory markers and IL-12 on 
ex-vivo DCs [51]. First, we wanted to measure the outcome of such a ligation in our 
setup. Thus, we treated BMDCs with different concentrations of the FGK45 
monoclonal anti-CD40 antibody and looked at their cytokine production and co-
stimulatory marker up-regulation (Fig. 18). At 10µg/ml, the antibody was able to 
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induce low levels of IL-12p40 and very low levels of IL-6, but not TNFα and IL-
12p70. At 50µg/ml, IL-6, IL-12p40 and TNFα were more strongly induced, but this is 
probably due to an antibody independent effect, as these results do not fit the 
titration curves. A low endotoxin contamination of the antibody stock could, for 
example, explain this result. The co-stimulatory markers, and particularly CD86, 
seem to be better read-outs, as they were strongly up-regulated upon CD40 ligation. 
CD40 fluorescence intensity was negatively correlated with anti-CD40 
concentration, indicating that the binding of this antibody was efficiently competing 
with the fluorochrome-associated anti-CD40 antibody. 
In this experiment we also assessed the ability of HES to modify the anti-CD40-
induced DC activation by co-treating some anti-CD40-activated DCs with 10µg/ml 
HES. Despite the fact that IL-6 and IL-12p70 were not induced by CD40 ligation, the 
other read-outs showed a HES immunomodulation of anti-CD40-activated cells 
comparable to the modulation of LPS-induced DCs (Fig. 19). Together, these results 
indicate that CD40 ligation can be used to assess the effect of HES on MyD88-/-
xTRIF-/- cells. 
Thus, we treated wild type and MyD88-/-xTRIF-/- BMDCs with anti-CD40 and a 
titration of HES. Unfortunately, the anti-CD40 activation did not work as well as in 
the previous experiment and, since this experiment was performed just before the 
end of the project, we were not able to repeat it. No IL-12p40 induction was 
detected. Nevertheless, the down-regulation of CD80, CD86 and MHC class II by 
the addition of HES on activated cells can clearly be seen on both cell strains (Fig. 
20). This confirms that HES does not require either MyD88 or TRIF to modulate the 
DCs and therefore excludes the participation of any TLR ligand in the process. 
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Figure	   16	   –	   The	   inhibition	   of	   the	   phosphoinositide-­3-­kinase	   does	   not	   alter	   the	  
HES	  immunomodulation	  of	  DCs.	  BMDCs	  were	  pre-­‐treated	  with	  DMSO,	  10nM,	  100nM	  or	  1µM	  wortmannin	  for	  30	  minutes	  before	  their	  stimulation	  with	  1µg/ml	  LPS	  in	  presence	  or	  absence	  of	  10µg/ml	  HES.	  After	  18	   hours	   incubation,	   cytokines	   levels	   in	   the	   supernatants	   were	   measured	   by	   ELISA.	  DMSO-­‐treated	  DCs	  did	  not	  produce	  IL-­‐12p70	  upon	  LPS	  and	  HES	  co-­‐treatment.	  Average	  values	  of	  triplicate	  wells	  are	  plotted	  for	  the	  DMSO-­‐treated	  groups.	  Error	  bars	  represent	  the	  SEM	  of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  Statistics	  shown	  compare	  the	  level	  of	  the	  DMSO	  control	  with	  one	  wortmannin	  treated	  group	  according	  to	  the	  position	  and	   colour	   of	   the	   symbol.	   Results	   of	   Student’s	   t	   test:	   non	   significant	   (ns)	   P>0.05,	  *P<0.05,	  ***P<0.001.	  Data	  are	  representative	  of	  two	  similar	  experiments.	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Figure	   17	   –	   HES	   down-­regulates	   TLR	   ligation-­induced	   IL-­6	   and	   TNFα 	   in	   both	  
MyD88-­/-­	  and	  TRIF-­/-­	  BMDCs.	  Wild	   type,	   MyD88-­‐/-­‐	   and	   TRIF-­‐/-­‐	   BMDCs	   were	   stimulated	   for	   18	   hours	   with	   a	  combination	  of	  one	  TLR	  ligand	  or	  media	  and	  one	  HES	  concentration	  or	  media.	  LPS	  was	  used	   at	   1µg/ml,	   CpG	   at	   10µg/ml,	   Pam3	   at	   100ng/ml	   and	   R848	   at	   1µg/ml.	   HES	  was	  added	   at	   0.1,	   1	   or	   10µg/ml.	   Cytokines	   levels	   in	   the	   supernatants	  were	  measured	   by	  ELISA.	  Error	  bars	  represent	  the	  SEM	  of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  This	  is	  representative	  of	  two	  similar	  experiments.	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Figure	   18	   –	   CD40	   ligation	   induces	   IL-­12p40	   production	   and	   co-­stimulatory	  
markers	  up-­regulation	  by	  BMDCs.	  BMDCs	   were	   stimulated	   with	   1,	   10	   or	   50	   µg/ml	   FGK45,	   an	   anti-­‐CD40	   antibody	  (αCD40),	  or	  kept	  in	  media	  for	  18	  hours.	  Cytokines	  concentrations	  in	  the	  supernatants	  were	  then	  measured	  by	  ELISA	  (panel	  A)	  and	  the	  DCs	  were	  stained	  for	  CD11c,	  MHC	  class	  II,	   CD40,	   CD80	   and	   CD86.	   Geometric	   means	   of	   the	   fluorescence	   intensity	   (MFI)	   for	  CD40,	  CD80,	  CD86	  and	  MHC	  class	  II	  of	  CD11c	  positive	  gated	  live	  cells	  were	  then	  plotted	  (panel	   B).	   Error	   bars	   represent	   the	   SEM	   of	   triplicate	   wells	   from	   the	   same	   BMDCs	  culture.	  Triplicates	  were	  pooled	  before	  surface	  staining.	  
B 
A 
48 
 
Figure	   19	   –	  HES	   is	   able	   to	   limit	   IL-­12p40,	   TNFα 	   production	   and	   co-­stimulatory	  
markers	  expression	  of	  anti-­CD40	  stimulated	  BMDCs.	  In	   addition	   to	   the	  usual	   immunomodulation	   assay,	  BMDCs	  were	   also	   stimulated	  with	  10µg/ml	   anti-­‐CD40	   antibody	   (αCD40)	   in	   presence	   or	   absence	   of	   10µg/ml	   HES.	  Cytokines	  concentrations	  in	  the	  supernatants	  were	  then	  measured	  by	  ELISA	  (panel	  A)	  and	   the	  DCs	  were	   stained	   for	  CD11c,	  MHC	   class	   II,	   CD40,	  CD80	  and	  CD86.	  Geometric	  means	  of	   the	   fluorescence	   intensity	   (MFI)	   for	  CD80,	  CD86	  and	  MHC	  class	   II	  of	  CD11c	  positive	   gated	   cells	   were	   the	   plotted	   (panel	   B).	   Error	   bars	   represent	   the	   SEM	   of	  triplicate	  wells	   from	  the	  same	  BMDCs	  culture.	  Triplicates	  were	  pooled	  before	  surface	  staining.	  
B 
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Figure	   20	   –	   HES	   down-­regulates	   CD80,	   CD86	   and	   MHC	   class	   II	   expression	   on	  
activated	  wild	  type	  and	  MyD88-­/-­xTRIF-­/-­	  in	  a	  similar	  manner.	  Wild	   type	   (WT)	   or	   MyD88xTRIF	   double	   knockout	   BMDCs	   were	   stimulated	   with	  10µg/ml	   HES,	   10µg/ml	   anti-­‐CD40	   antibody	   (αCD40)	   or	   a	   combination	   of	   anti-­‐CD40	  and	  0.5,	  1,	  5,	  or	  10	  µg/ml	  HES.	  After	  18	  hours	  incubations,	  cells	  were	  stained	  for	  CD11c,	  MHC	  class	  II,	  CD40,	  CD80,	  CD86	  and	  the	  geometric	  mean	  of	  the	  fluorescence	  intensity	  was	   plotted.	   Error	   bars	   represent	   the	   SEM	   of	   triplicate	   wells	   from	   the	   same	   BMDCs	  culture.	  Results	  of	  Student’s	  t	  test:	  *	  P<0.05,	  **	  P<0.01,	  ***P<0.001.	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3.5 HES	  fractions	  analysis	  
In parallel with our attempts to identify the molecular pathway targeted by HES, we 
also tried to define which particular compounds of this complex mixture were 
responsible for the global effect. To this end, we compared the immunomodulatory 
properties of 24 HES molecular weight fractions to the effect of the whole product. 
These fractions, resulting from a size fractionation on a Superdex 200 column (GE 
Health care), were kindly provided by James Hewitson and Kara Filbey. 
First, we have to mention that at least another research group performed the same 
kind of HES size fractionation combined with functional assays to determine the 
immunoactive compounds of HES. In 2006, Rzepecka et al. [40, 52] defined an 
active fraction of HES by looking at the ability of the fractions to inhibit the antigen-
specific cellular proliferation of mesenteric lymph node cells. This allowed them to 
narrow down the number of molecular targets to seven. In a second paper [40], they 
suggested a mechanism involving interaction between H. polygyrus calreticulin 
(HpCRT) and the DC scavenger receptor-A. Following these results, Mark Pearson, 
a former researcher in the lab, had purified bacterially expressed recombinant 
HpCRT in with the hope of developing vaccines. Therefore, in order to avoid going 
through a similar process in our setup and end up with the same candidate, we tried 
to directly treat BMDCs with recombinant HpCRT and see if it had an effect. 
To begin with, we had to remove the bacterial contaminants from the protein 
solution to avoid a direct activation of the TLR pathway that could mask anti-
inflammatory effects. This was performed by the repeated incubations with Triton 
X114 followed by centrifugation. This reagent forms micelles that trap LPS. The 
centrifugations separate the solution into a protein-containing aqueous phase and a 
LPS-containing lipid phase. We then treated LPS-activated DCs with different 
concentrations of HpCRT and noticed that this protein had no immunomodulatory 
effects (Fig. 21). Moreover, HpCRT seemed to activate the cells to a certain extent 
by itself. Nevertheless, this “fishing” experiment cannot exclude a possible glycan-
mediated effect of native HpCRT, as the recombinant protein was produced by 
bacteria and therefore lacks post-translational modifications. 
Next, we conducted our own fractions analysis. We co-treated BMDCs with 1µg/ml 
LPS and 10µg/ml HES or the equivalent of 10µg/ml of each fraction as estimated 
from the initial amount of HES run through the size fractionation column and the 
ratio of the fraction volume to the total elution volume. The down-regulation of the 
inflammatory cytokines of each fraction was compared to the maximal 
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immunomodulation achieved by total HES and if this ratio reached more than 40% 
the fraction was highlighted on the graph (Fig. 22). This experiment was repeated 
on two different BMDCs cultures and, after comparison of the percentages of 
cytokine inhibition, we concluded that fraction 14 was the most potent in limiting IL-
6, IL-12p70 and TNFα production, even though fractions 8, 9 and 10 also displayed 
immunomodulatory properties (Table 3). 
From there, we decided to compare the protein as well as the glycan content of 
fraction 14 with its neighbouring fractions 13 and 15 that showed weak 
immunomodulatory properties with the hope of finding few differences between 
these size-related fractions. Regarding the proteins, we first performed 2D SDS-
PAGE of these three fractions and silver stained them (pictures in Appendix, Fig. S 
3 and S 4). As the patterns were very different, it was impossible to select specific 
spots for a targeted mass spectrometry analysis. Therefore, we considered sending 
the whole fraction for a global mass spectrometry analysis. However, as another 
fraction had already been sent for the same purpose, we decided to wait for the 
results of this other fraction before sending fraction 14. Unfortunately, the mass 
spectrometry turned out not to be as useful as expected, since more than a hundred 
identities were detected in the other fraction, suggesting that the size fractionation 
on the Superdex column was not sufficient to significantly reduce the number of 
molecular targets in a single fraction. For this reason, fraction 14 has not yet been 
analysed by mass spectrometry. Ion-exchange chromatography could offer another 
approach for HES fractionation and, hopefully, once the functional activity of both 
weight and charge fractions will have been assessed, it will be possible to analyse a 
limited number of proteins by mass spectrometry. 
For the glycan comparison, we first assessed the binding of seven biotinylated 
lectins available in the lab to the whole set of HES fractions (Fig. 23) to determine 
which lectin could be used to reveal glycans on 2D gels. Concanavalin A, which 
binds α-D mannose and α-D glucose residues, was the only one to show an 
increase in OD on fraction 14 compared to uncoated wells. Following this result, we 
ran two 2D SDS-PAGE of fraction 14 in parallel, silver stained one gel and 
performed a western blot for Con A on the other. Unfortunately, no specific Con A 
binding spot appeared, because of a very high non-specific binding background and 
this problem has not yet been solved. 
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Figure	  21	  –	  Recombinant	  H.	  polygyrus	   calreticulin	  does	  not	  reduce	  LPS-­induced	  
inflammatory	  cytokines.	  BMDCs	  were	  stimulated	  for	  18	  hours	  with	  10µg/ml	  HpCRT	  or	  1µg/ml	  LPS	  in	  presence	  or	   absence	   of	   10µg/ml	   HES,	   1,	   10,	   100,	   1000,	   10000	   ng/ml	   HpCRT.	   Supernatant	  cytokines	   levels	  were	  measured	  by	  ELISA.	   Error	   bars	   represent	   the	   SEM	  of	   triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  This	  is	  representative	  of	  two	  similar	  experiments.	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Figure	   22	   –	   HES	   size	   fraction	   number	   14	   is	   the	   most	   efficient	   in	   limiting	   the	  
inflammatory	  cytokine	  production	  by	  LPS-­stimulated	  BMDCs.	  BMDCs	   were	   co-­‐stimulated	   for	   18	   hours	   with	   1µg/ml	   LPS	   and	   10µg/ml	   HES	   or	   the	  approximate	  equivalent	  protein	  amount	  of	  each	  HES	  size	   fraction.	  Cytokines	   levels	   in	  the	  supernatants	  were	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  SEM	  of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  Percentages	  of	  relative	  inhibition	  were	  calculated	  as	   the	   ratio	   of	   the	   difference	   between	   the	   cytokine	   level	   induced	   by	   the	   LPS	   and	  LPS/Fraction	  treated	  groups	  and	  the	  difference	  between	  the	  LPS	  and	  LPS/HES	  treated	  groups.	  Panels	  A	  and	  B	  display	  results	  from	  two	  independent	  experiments.	  
A B 
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Fraction number 3 4 5 8 9 10 11 14 15 
IL-6 BD-14 57 42 - 59 43 52 - 41 - 
IL-6 BD-14 - - - - 49 49 - 54 - 
IL-12p70 BD-14 51 - 41 40 42 55 55 57 43 
IL-12p70 BD-17 - - - 54 65 69 - 87 48 
TNFα  BD-14 - - - - - - - 44 - 
TNFα  BD-17 - - - 41 - - - 73 - 
	  
Table	   3	   -­	   Summary	   of	   the	   percentages	   of	   total	   cytokine	   inhibition	   achieved	   by	  
fractions	  with	  detected	  immunomodulatory	  activity.	  Percentages	   rounded	   to	   the	   lower	   integer	   are	   displayed	   if	   higher	   than	   40%.	   The	  formula	  used	  to	  obtain	  these	  numbers	  was:	  
Cytokine	  level	  upon	  LPS	  treatment	  -­	  Cytokine	  level	  upon	  LPS+HES	  fraction	  treatment	  
Cytokine	  level	  upon	  LPS	  treatment	  -­	  Cytokine	  level	  upon	  LPS+Total	  HES	  treatment	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Figure	  23	  –	  Biotinylated	  lectins	  binding	  analyses	  on	  HES	  size	  fractions.	  To	   detect	   highly	   expressed	   glycans	   in	   the	   different	   HES	   fractions,	   ELISA	   plates	  were	  coated	   with	   HES	   fractions,	   the	   estimated	   equivalent	   protein	   amount	   of	   HES	   or	   left	  uncoated.	  After	  a	  blocking	  step,	  biotinylated	  lectins	  were	  added	  and	  then	  revealed	  with	  the	   Strep-­‐HRP/ABTS	   system.	   Optical	   density	   (OD)	   values	   of	   single	   wells	   for	   the	  fractions	  or	  mean	  of	  triplicate	  wells	  for	  the	  positive	  and	  negative	  controls	  were	  plotted.	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3.6 HES	   binds	   CD24	   on	   the	   surface	   of	   DCs,	   but	   the	   interaction	  with	  
this	  molecule	  is	  not	  critical	  for	  the	  immune	  modulation.	  
The final method we used to study the molecular interaction between HES and DCs 
was to use biotinylated HES, provided by James Hewitson, for flow cytometry 
analysis on DCs. From the beginning the focus was CD24, a surface glycoprotein, 
which was shown by Hewitson to be the target of HES on B cells (unpublished 
data). 
Preliminary analysis showed that biotinylated HES was also binding DCs and that 
this binding was correlated with CD24 positive cells (data not shown). Nevertheless, 
as nearly all our BMDCs expressed CD24, it was necessary to wait for CD24-/- mice 
to confirm the binding of biotinylated HES to DCs through this molecule. As only two 
CD24-/- mice were available before the end of the project, it was decided to go a bit 
beyond the scope of this work and also derive macrophages from this precious bone 
marrow. For simplicity, the same assay was performed on both cell types. 
First, wild type and CD24-/- bone marrow-derived macrophages (BMDMs) were 
stained for CD11b, CD11c, F4/80, MHC class II, CD40, CD80, CD86, CD24 and 
different concentrations of either biotinylated HES or biotinylated H. polygyrus 
extract (Hex), which is a simple homogenate of adult H. polygyrus worms. Biotin 
was then revealed with a second staining step with APC-conjugated streptavidin. 
When checking that macrophages were not activated and that the wild type and 
knockout populations were similar, it was noticed that the CD24-/- BMDCs expressed 
slightly higher levels of F4/80 than the wild type, but all the other measured markers 
showed comparable levels of expression (data not shown). Then gating for live, 
CD11b+F4/80+ cells, the level of streptavidin binding was plotted (Fig. 24 and 
Appendix Fig. S 5 and S 6). A slight reduction of HES binding to CD24-/- 
macrophages compared to wild type cells was seen, but the two titration curves 
remained very similar. Biotinylated Hex did not bind macrophages at all confirming 
that HES binding was specific. This result proves that HES interacts with BMDMs 
and suggest that the contribution of the interaction with CD24 is minimal in regard to 
the global binding. It should be mentioned here that James Hewitson performed the 
same analysis on B cells and showed that biotinylated HES was unable to bind 
CD24-/- B cells, confirming that the interaction of HES with B cells was entirely CD24 
dependent. Thus, it is certain that HES actually interacts with CD24, even though 
this binding activity does not seem very important on macrophages. 
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Because of this limited difference in the cell binding, no major divergence between 
the wild type and the knockout cells was expected in term of functional response to 
HES, but macrophages were nevertheless stimulated with LPS, LPS and a titration 
of HES or LPS and a titration of hiHES (Fig. 25). Similarly to the DC assay 105 cells 
were plated per well, but the assay was performed in flat bottom plates to allow for 
adhesion of macrophages. First of all, it must be pointed out that the levels of 
cytokines secreted by the macrophages in this setup were very low and no IL-12p70 
was detectable. Moreover, CD24-/- macrophages showed higher cytokines 
production upon LPS and HES co-treatment than upon LPS ligation only (Fig. 25). 
This should normally not occur and the experiment should therefore be repeated. 
Nonetheless, one can still see a dose-dependent down-regulation of LPS-induced 
IL-6 by HES in both the wild type and the CD24-/- group. The reduction of IL-6 level 
between the LPS group and the group treated with LPS and 10µg/ml HES was 
significant according to a Student’s t test. Once again, hiHES did not show any 
dose-dependent effect. No significant variations of the other measured cytokines 
were observed even if there was a slight down-regulation of TNFα with 10µg/ml 
HES. After this assay, macrophages were stained for CD11b, F4/80, MHC class II, 
CD40, CD80 and CD24. The same kind of weak HES dose-dependent down-
regulation of MHC class II and CD40 could be seen on both cell types (data not 
shown). This could be due to a technical failure in the purification process of the 
HES batch used in this experiment. However, if this trend is confirmed, it would 
suggest that the HES down-regulates inflammatory cytokine production of BMDM in 
a similar way it does for DCs and that this modulation is at least not fully CD24 
dependent. 
Second, wild type and CD24-/- BMDCs were stained for CD11c, MHC class II, CD40, 
CD80, CD86, CD24 and different concentrations of biotinylated HES or biotinylated 
Hex. As for macrophages, DCs were found not to be activated and live, CD11c 
positive gated cell populations were similar. As expected, biotinylated HES bound 
wild type DCs in a dose-dependent manner, whereas the negative control, 
biotinylated Hex did not (Fig. 26 and Appendix Fig. S7 and S8). Interestingly, HES 
was able to bind CD24-/- DCs, but the interaction was strongly reduced. Therefore, it 
appears that HES binds at least two molecules on DCs, one of them being CD24. 
This is really remarkable in regard to Liu et al. paper [53] and their hypothesis that 
interactions between DAMPs, CD24 and SiglecG could lead to an inhibition of the 
NF-κB pathway. 
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Therefore, to assess if HES was down-regulating the production of inflammatory 
cytokines through CD24, we performed once again the usual immunomodulation 
assay on wild type and CD24-/- BMDCs (Fig. 27). First of all, it was seen that, 
similarly to macrophages, CD24-/- BMDCs were producing slightly less inflammatory 
cytokines than the wild type cells upon LPS stimulation, but none of these 
differences was significant according to Student’s t tests. When co-stimulated, both 
groups displayed a HES, but not hiHES, dose-dependent inhibition of the 
inflammatory cytokines, suggesting that the immunomodulatory process is CD24 
independent. However, for the same reason as in the macrophages assay, the 
immunomodulatory effects of HES were not as strong as expected from previous 
experiments. The inhibition of TNFα for example was not significant for both groups, 
nor was inhibition of IL-6 on CD24-/- DCs. Thus, it will be needed to repeat these 
results in order to compare the efficiency of the HES inhibition on both DCs sets, 
since we cannot exclude that the HES immunomodulation could be weaker in the 
absence of CD24. 
At the end of the incubation, DCs were stained for CD11c, MHC class II and co-
stimulatory markers. Unfortunately, the LPS-pulsed wild type cells did not show a 
strongly activated phenotype and the HES induced immunomodulation was difficult 
to see. However, the assay worked well for CD24-/- cells, which displayed a clear 
down-regulation of all the markers, suggesting that co-stimulatory markers could be 
modulated to the same extent in CD24-/- and wild type DCs (Fig. 28). Once again, 
this must be confirmed in an experiment with a properly working wild type control. 
In addition, the comparison of the biotinylated HES binding curves of macrophages 
and DCs (Fig. 25 and 27) indicated that the global avidity of HES compounds was 
higher for the macrophages than for the DCs. Moreover, the shift of the binding 
curve in the absence of CD24 seemed high for DCs, but minimal for macrophages. 
Together with Hewitson’s results, these two experiments suggest that HES 
components bind CD24, but interactions with other receptors also occur. This or 
these receptor(s) are not expressed on spleen isolated CD90+ B cells, mildly 
expressed on GM-CSF grown BMDCs and highly expressed on M-CSF grown 
BMDM. In addition, CD24 ligation does not seem crucial for the ability of HES to 
modulate DC and macrophage activation states. 
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Figure	  24	  –	  Biotinylated	  HES	  binds	  to	  wild	  type	  and	  CD24-­/-­	  bone	  marrow-­derived	  
macrophages	  in	  a	  similar	  manner.	  Day	  7	  wild	  type	  and	  CD24-­‐/-­‐	  BMDMs	  were	  stained	  for	  CD11b,	  CD11c,	  F4/80,	  MHC	  class	  II,	   CD40,	   CD80,	   CD86,	   CD24	   and	   different	   concentrations	   of	   biotinylated	   HES	   or	  biotinylated	  Hex.	  The	  complete	  analysis	  is	  presented	  in	  appendix.	  Only	  live	  and	  CD11b+	  F4/80+	   gated	   cells	   treated	  with	   the	   top	   concentrations	   (4µg/ml)	   of	   biotinylated	  HES	  and	  Hex	  or	  no	  antigen	  are	  displayed	  here	  (panel	  A).	  HES	  or	  Hex	  binding	  on	  live	  CD11c+	  cells,	  as	  determined	  by	  the	  percentage	  of	  biotin	  positive	  cells,	  was	  then	  plotted	  for	  the	  whole	  titration	  (panel	  B).	  Horizontal	  lines	  show	  the	  value	  of	  untreated	  controls.	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Figure	   25	   –	  Wild	   type	   and	   CD24-­/-­	   bone	  marrow	  derived	  macrophages	   respond	  
similarly	  to	  LPS	  and	  HES	  or	  hiHES	  co-­stimulation.	  Wild	   type	   and	   CD24-­‐/-­‐	   BMDMs	   were	   stimulated	   with	   1µg/ml	   LPS,	   10µg/ml	   HES,	  10µg/ml	  hiHES	  or	  a	  combination	  of	  LPS	  and	  various	  concentrations	  of	  HES	  or	  hiHES.	  18	  hours	   later,	   cytokines	   levels	  were	  measured	   in	   the	   supernatants	   by	   ELISA.	   IL-­‐12p70	  was	   not	   detected.	   Error	   bars	   represent	   the	   SEM	   of	   triplicate	   wells	   from	   the	   same	  BMDMs	  culture.	  Horizontal	  lines	  show	  the	  average	  of	  triplicate	  wells	  treated	  with	  one	  or	   no	   stimulus.	   Untreated	   controls	   did	   not	   produce	   a	   detectable	   level	   of	   TNFα.	   IL-­‐12p40	   was	   also	   below	   the	   detection	   threshold	   for	   the	   HES-­‐,	   hiHES-­‐	   and	   untreated	  controls.	   Statistics	   shown	   compare	   the	   LPS-­‐treated	   group	  with	   the	   cells	   treated	  with	  LPS	  and	  10µg/ml	  HES.	  Results	  of	  Student’s	  t	  test:	  non	  significant	  (ns)	  P>0.05,	  *P<0.05,	  ***P<0.001.	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Figure	  26	  -­	  CD24	  deficiency	  strongly	  reduces	  biotinylated	  HES	  binding	  to	  BMDCs	  Day	  10	  wild	  type	  and	  CD24-­‐/-­‐	  BMDCs	  were	  stained	  for	  CD11c,	  MHC	  class	  II,	  CD40,	  CD80,	  CD86,	  CD24	  and	  different	  concentrations	  of	  biotinylated	  HES	  or	  biotinylated	  Hex.	  The	  complete	   analysis	   is	   presented	   in	   appendix.	   Only	   live	   and	   CD11c+	   gated	   cells	   treated	  with	   the	   top	   concentrations	   (4µg/ml)	   of	   biotinylated	  HES	   and	  Hex	   or	   no	   antigen	   are	  displayed	  here	  (panel	  A).	  HES	  or	  Hex	  binding	  on	  live	  CD11c+	  cells,	  as	  determined	  by	  the	  percentage	  of	  biotin	  positive	  cells,	  was	   then	  plotted	   for	   the	  whole	   titration	   (panel	  B).	  Horizontal	  lines	  show	  the	  value	  of	  untreated	  controls.	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Figure	   27	   –	   HES,	   but	   not	   hiHES,	   down-­regulates	   the	   inflammatory	   cytokines	  
production	  of	  LPS-­stimulated	  CD24-­/-­	  BMDCs.	  Wild	   type	   and	   CD24-­‐/-­‐	   BMDCs	   were	   stimulated	   with	   1µg/ml	   LPS,	   10µg/ml	   HES,	  10µg/ml	  hiHES	  or	  a	  combination	  of	  LPS	  and	  various	  concentrations	  of	  HES	  or	  hiHES.	  18	  hours	   later,	   supernatants	   cytokines	   levels	   were	   measured	   by	   ELISA.	   Error	   bars	  represent	   the	   SEM	   of	   triplicate	  wells	   from	   the	   same	  BMDCs	   culture.	   Horizontal	   lines	  show	  the	  average	  of	  triplicate	  wells	  treated	  with	  one	  or	  no	  stimulus.	  HES-­‐,	  hiHES-­‐	  and	  untreated	  cells	  did	  not	  produce	  detectable	  levels	  of	  IL-­‐6	  and	  IL-­‐12p70.	  Statistics	  shown	  compare	   the	   LPS-­‐treated	   group	   with	   the	   cells	   treated	   with	   LPS	   and	   10µg/ml	   HES.	  Results	  of	  Student’s	  t	  test:	  non	  significant	  (ns)	  P>0.05,	  *P<0.05,	  ***P<0.001.	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Figure	  28	  –	  HES	  inhibits	  LPS-­induced	  up-­regulation	  of	  co-­stimulatory	  markers	  on	  
the	  surface	  of	  CD24-­/-­	  BMDCs.	  After	   the	   assay	   described	   in	   figure	   27,	   BMDCs	  were	   stained	   for	   CD11c,	  MHC	   class	   II,	  CD80,	   CD86.	   Gates	   were	   applied	   for	   live,	   CD11c	   expressing	   cells	   and	   the	   geometric	  mean	  of	  the	  fluorescence	  intensity	  for	  the	  other	  markers	  was	  plotted.	  Concentrations	  in	  brackets	   are	   in	   µg/ml.	   Single	   wells	   were	   stained	   and	   statistics	   are	   therefore	   not	  available.	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3.7 DC	  adoptive	  transfer	  
Finally, we wanted to see if the in vitro modulations witnessed in this project were 
correlated with a downstream effector T cell response in vivo. In this view, we 
decided to ask three main questions. What kind of Th response profile does HES 
induce? Is HES able to modulate the Th response to a bacterial pathogen like it 
modifies DCs response to LPS and does heat-inactivated HES have the same 
properties as HES?  
To answer these questions, we chose a model already used by John Grainger, 
based on the fact that DCs are able to differentially process several antigens by 
trafficking them in separate compartments [9]. First, we stimulated BMDCs with 
PBS, HES, hiHES, heat-inactivated P. acnes extract (Pa) or a combination of these 
antigens for 18 hours. Killed P. acnes extract was the typical Th1 inducer used in 
Cervi et al.’s paper [9] to stay closer to the infection setup, where DCs are exposed 
to whole bacteria rather than only one of their many cell wall components. Then, we 
checked that Pa, which contains multiple different PAMPs, induced DCs activation 
in the same way as LPS did in the in vitro assays. Co-stimulatory marker expression 
and cytokine production were measured at the end of the incubation and the 
activation of DCs by Pa, the tolerance of HES and hiHES as well as the ability of 
HES, but not hiHES, to inhibit Pa-induced DCs activation were confirmed (Fig. 29). 
Next, we washed the harvested DCs and adoptively transferred them into the 
peritoneal cavity of naïve BALB/c recipients. One week later, T cells were recovered 
from spleens and draining lymph nodes and re-stimulated with an anti-CD3 antibody 
to measure the polyclonal response, or with HES or Pa to assess the antigen 
specific response. After 72 hours incubation, cytokine levels were measured in the 
supernatants. 
The variability of the outcome of the in vivo transfers was high and it is difficult to 
argue that the results presented here show any real immunomodulation because Pa 
never really induced the expected strong Th1 response. Nonetheless, we will try to 
identify the dominant patterns that were conserved throughout the experiments. 
First, in the lymph nodes, no significant antigen-specific response was detected, 
suggesting that either the numbers of DCs injected were not sufficient or that these 
cells were unable to properly migrate to reach and activate T cells. Accordingly, the 
polyclonal response was not strongly polarised even though the HES- and hiHES-
pulsed group tended to be dominated by Th2-related cytokines, whereas Pa pulsing 
clearly induced a Th1/Th17 type response (Fig. 30). To simplify, IL-5, IL-13 and IL-
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10 graphs, which displayed similar patterns to IL-4, were not shown on this figure. 
Both co-pulsed groups showed intermediate responses, with relatively high levels of 
all measured cytokines except for IFNγ that was down-regulated compared to the 
Pa-pulsed group, suggesting that both HES and hiHES are able to limit the 
development of a Th1-type response. However, this down-regulation was not 
significant. 
In the spleen, the non-specific response to HES- and hiHES-pulsed DCs seemed to 
induce Th2-related cytokine production, but this was not significant compared to the 
αCD3-induced response of the un-pulsed DCs group, since this group produced 
relatively high levels of all the measured cytokines without particular polarisation 
(Fig. 31). Nevertheless, the levels of IL-4 produced by HES- and hiHES-pulsed 
DCs-activated T cells were significantly higher than the IL-4 production of the Pa-
pulsed group, whereas their IL-17 and IFNγ production was low. Together, these 
results suggest that both HES- and hiHES-pulsed DCs are able to polarise T cells 
so that they tend to induce a Th2-type response once they are activated by a non-
specific stimulus. In this setup, it could also be interesting to compare the response 
of non-injected mice to the response of mice injected with un-pulsed DCs to see if 
the DCs injection by itself is the cause of the relatively high cytokine levels in 
response to anti-CD3. 
T cells activated by Pa-pulsed DCs did not produce Th2-related cytokines, but 
induced a strong Th17 response. However, and as opposed to what we saw in the 
lymph nodes, they did not stimulate the expected Th1 response. The Pa-pulsed 
group was strongly heterogeneous with two mice that did not respond at all and two 
mice that were producing very high levels of IFNγ even in the absence of re-
stimulating antigen. If we look at the only other experiment where anti-CD3 re-
stimulation was performed (Fig. 32), it seems that Pa-pulsed DCs polarise T cells 
toward a Th1-type response. This let us hope that, after an optimisation of the 
protocol, a strong Th1 induction by Pa could be achieved in this model and therefore 
allow for a convincing assessment of the HES and hiHES ability to skew the 
Th1/Th2 balance upon adoptive transfer of co-stimulated DCs. The same figure also 
suggests that HES is able to inhibit the Th1 response to P. acnes. Unfortunately, the 
hiHES and hiHES/Pa groups were lacking in this experiment because of the poor 
yield of that particular BMDCs culture, but, on figure 31, we see that the hiHES/Pa 
co-pulsed group shows the same response as the HES/Pa group, suggesting that 
they could behave in a similar way. 
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The two co-pulsed groups showed a mixed Th response. Their levels of IL-4 were 
reduced compared to the HES- and hiHES-pulsed groups, but higher than the Pa-
pulsed group. No induction of IFNγ was detectable, but neither HES nor hiHES 
seemed able to decrease the Pa-induced Th17 response. 
IL-17 was the only measured cytokine that showed strong responses upon antigen-
specific re-stimulation (detailed on Fig. 31B). Similarly to the polyclonal response, 
Pa re-stimulation induced similar levels of IL-17 in the Pa-pulsed and in both co-
pulsed groups, confirming the inability of HES or hiHES to modulate the Th17 
response to Pa. Interestingly, HES re-stimulation even caused an increase of IL-17 
levels in the HES and HES/Pa-pulsed, but not the hiHES and hiHES/Pa-pulsed 
groups. The unexpected HES-specific IL-17 production in the HES-pulsed group 
was not repeated in any other experiments. On the contrary, the same effect in the 
HES/Pa co-pulsed group was to see in three out of the four transfer experiments. 
The fact that the HES-specific IL-17 production was higher than the Pa-induced 
level in the HES/Pa co-pulsed group, but not in the hiHES/Pa group suggest that the 
heat-labile components of HES could be able to skew the immune response toward 
a Th17 rather than a Th1 response in the physiologically relevant case of the 
simultaneous uptake of both H. polygyrus and bacterial products by DCs. 
The regulatory response-associated IL-10 production was similar to the IL-4 pattern 
(data not shown). Anti-CD3 induced high levels of IL-10 in both HES- and hiHES-
pulsed groups, low levels in the Pa group and intermediate levels in the co-pulsed 
groups. Together, these results suggest that HES-pulsed DCs and P. acnes-pulsed 
DCs polarise T cells toward different Th profiles and that HES as well as hiHES can 
modify the response to P. acnes upon co-treatment. Moreover HES, but not hiHES, 
seems able to favour a Th17 rather than a Th1 response upon DCs co-simulation. 
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Figure	  29	  –	  P.	  acnes	  activates	  DCs	  similarly	  to	  LPS	  and	  HES,	  but	  not	  hiHES,	  is	  able	  
to	  inhibit	  this	  activation.	  With	   the	   aim	   of	   transferring	   them	   in	   vivo,	   BMDCs	  were	   stimulated	  with	   10µg/ml	  P.	  
acnes	  extract,	  25µg/ml	  HES,	  25µg/ml	  hiHES	  or	  a	  combination	  of	  Pa	  and	  HES	  or	  Pa	  and	  hiHES.	  After	  18	  hours,	  supernatant	  were	  harvested	  and	  cytokines	  concentrations	  were	  measured	  by	  ELISA	  (panel	  A,	  B	  and	  C).	  Error	  bars	  represent	  the	  SEM	  of	  triplicate	  wells	  from	  the	  same	  BMDCs	  culture.	  n.d.	  stands	  for	  not	  detected.	  DCs	   were	   washed	   and	   injected	   into	   BALB/c	   recipients	   and	   the	   left	   over	   cells	   were	  stained	  in	  single	  wells	  for	  their	  surface	  expression	  of	  CD11c,	  MHC	  class	  II,	  CD80,	  CD86	  and	  CD40.	  A	  gate	  for	  live	  cells	  expressing	  CD11c	  was	  applied	  and	  the	  geometric	  mean	  of	  the	   fluorescence	   intensity	   of	   the	   other	   markers	   was	   plotted	   (panel	   D).	   Results	   of	  Student’s	   t	   test:	   non	   significant	   (ns)	   P>0.05,	   **P<0.01,	   ***P<0.001.	   Data	   are	  representative	  of	  four	  similar	  experiments.	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Figure	  30	  –	  Polyclonal	  and	  antigen-­specific	  Th	  responses	  induced	  in	  the	  draining	  
lymph	  nodes	  by	  adoptive	  transfer	  of	  HES-­,	  hiHES-­,	  Pa-­	  and	  co-­pulsed	  DCs.	  BMDCs	   stimulated	   following	   the	   protocol	   described	   in	   figure	   29	  were	   injected	   intra-­‐peritoneally	  in	  naïve	  BALB/c	  recipients.	  Seven	  days	  later,	  draining	  lymph	  nodes	  of	  the	  peritoneal	  cavity	  were	  mashed	  and	  the	  cells	  were	  re-­‐stimulated	  with	  2µg/ml	  anti-­‐CD3	  antibody	   (αCD3),	   10µg/ml	  HES,	   1µg/ml	  Pa	   or	   left	   in	  media.	  After	   72	  hours,	   cytokine	  levels	  in	  the	  supernatants	  were	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  standard	  deviation	   (SD)	  of	   four	  different	  animals.	   IL-­‐5,	   IL-­‐13	  and	   IL-­‐10	  production	   (not	   shown	  here)	  was	  very	  similar	  to	  the	  IL-­‐4	  pattern.	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Figure	  31A	  -­	  Polyclonal	  and	  antigen-­specific	  Th	  responses	  induced	  in	  the	  spleen	  
by	  adoptive	  transfer	  of	  HES-­,	  hiHES-­,	  Pa-­	  and	  co-­pulsed	  DCs.	  Following	  the	  protocol	  described	  in	  figures	  29	  and	  30,	  splenocytes	  were	  re-­‐stimulated	  for	   3	   days	   and	   cytokine	   levels	   in	   the	   supernatants	   measured	   by	   ELISA.	   Error	   bars	  represent	  the	  SD	  of	  four	  different	  animals.	  IL-­‐5,	  IL-­‐13	  and	  IL-­‐10	  production	  (not	  shown	  here)	  was	  very	  similar	  to	  the	  IL-­‐4	  pattern.	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Figure	  31B	  –	  Detail	  from	  figure	  31A	  showing	  the	  IL-­17	  production	  in	  response	  to	  
antigen-­specific	  re-­stimulation.	  Results	  of	  Student’s	  t	  test:	  **	  P<0.01,	  non	  significant	  (ns)	  P>0.05	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Figure	  32	  –	  Splenocyte	  interferon	  γ 	  response	  to	  HES-­,	  Pa-­	  and	  co-­pulsed	  DCs	  from	  
a	  separate	  experiment.	  The	   exact	   same	   protocol	   as	   in	   figure	   31	  was	   followed	   in	   this	   experiment	   lacking	   the	  hiHES	  and	  hiHES/Pa	  groups,	   but	   showing	   the	   expected	  Th1	   response	   induced	  by	  Pa-­‐pulsed	  DCs.	  Error	  bars	  represent	  the	  SD	  of	  four	  different	  animals.	  The	  first	  part	  of	  the	  label	   gives	   the	   DC	   priming	   stimulus.	   The	   second	   part	   shows	   the	   re-­‐stimulation	  stimulus.	  Results	  of	  Student’s	  t	  test:	  **	  P<0.01,	  ***	  P<0.001,	  non-­‐significant	  (ns)	  P>0.05.	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4 Discussion 
The study of the interactions between a parasite and its host are as fascinating as 
the mechanisms behind them are complex. The strategies applied by both 
organisms are the result of a very long co-evolution during which one species had to 
adapt to any new feature of the other. Therefore, the molecular interactions can be 
quite intricate and difficult to understand, but most of the times the final result tend 
to an equilibrium that allows both organisms to survive. 
In the case of intestinal helminth infections, the goal of the worms is to keep the 
immune system in a low state of activation in order to avoid being expelled from the 
gut. Inducing a regulatory response seems a good way to go and H. polygyrus has 
indeed developed this ability [39]. Nevertheless, some level of effector response will 
always remain, as foreign antigens will be presented to T cells. The definition of the 
best T helper environment from the worm’s point of view is a bit more problematic. A 
Th1/Th17-type response is definitely one to avoid, as it would induce tissue damage 
potentially allowing bacterial infection and would be equally harmful for the host and 
the parasite that would then have to deal with a highly inflammatory environment. 
On the other hand, a Th2-type response would maintain the integrity of the gut, but 
is likely to lead to the worm expulsion through increased mucus secretion and 
peristaltic movements of the intestinal smooth muscles [54]. Therefore, the survival 
of a worm in a particular animal for an extended period suggest that this parasite 
has managed to skew the immune response of its host, in order to maintain the 
perfect balance between tolerance, inflammation and expulsion. 
From the host point of view, mounting an efficient Th2 response seems crucial to 
expel the worms, at least in the H. polygyrus model [4, 55, 56]. However, as gut 
parasites are not proliferating inside their host, they do not represent an immediate 
life-threatening condition. Therefore, maintaining low levels of inflammatory 
cytokines at the invasion site is actually also beneficial to the host, as this will avoid 
a chronic pathogenesis linked with extended tissue damage. Thus, host and 
parasite have a common interest in keeping the Th1 response low, but have 
different aims in regard to the Th2 response. This could explain why the 
excretory/secretory products of H. polygyrus are so efficient in down-regulating the 
inflammatory cytokine production of DCs as both organisms actually benefit from a 
local anti-inflammatory environment in the gut mucosa. This down-regulation could 
thus as well be seen as an optimised host response to the parasite. 
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As DCs have been shown to be crucial in the induction of a Th2-type response [57], 
the question is now to know if HES can modify their ability to induce Th2 cells. In the 
acute intestinal infection model Nippostrongylus brasiliensis, in vivo transfer of 
excretory/secretory-pulsed BMDCs have been reported to induce a strong specific 
Th2 response [58], which may be the cause of the quick elimination of the worms. 
Although H. polygyrus is able to invade mice for an extended period, John Grainger 
described a similar Th2 induction upon HES or hiHES-pulsed BMDCs transfer and 
HES re-stimulation. In order to have an in vivo assay available to test potential HES 
immunoactive molecules or DCs deficient for some key molecules, we repeated 
Grainger’s work, but when we transferred HES-pulsed DCs intra-peritoneally, we 
were not able to detect a strong antigen-specific Th2 cytokines production upon 
spleen or draining lymph node T cell re-stimulation. This could be due to several 
parameters that should still be optimised, like the number of DCs injected that was 
sufficient for Grainger’s experiments in C57BL/6, but may not be in BALB/c. Another 
issue could be the ability of DCs to reach the lymph nodes. Thus, it would be a good 
idea to repeat that experiment with fewer groups and titrate the number of DCs 
injected. In addition, injections in the footpad followed by re-stimulation of popliteal 
lymph nodes could be tried. We already used this model with another protocol of 
DCs pulsing that did not turn out to work, but this type of injection at least showed a 
huge increase of the size of popliteal lymph nodes suggesting a good migration of 
the DCs. It would be interesting as well to pulse DCs with another strong Th2 
inducer like Nippostrongylus brasiliensis excretory/secretory products (NES) or SEA 
to compare their ability to induce Th2-related cytokines in this setting with the HES-
induced Th2 cytokines. 
Concerning the non-specific response induced by anti-CD3 re-stimulation, the 
general pattern seems to fit the hypothesis stating that HES induces a Th2-type 
response with some regulatory features. The Th1 induction expected with Pa-
pulsing was not achieved, and, for this reason, we cannot argue that the HES co-
treatment reduces the Pa induced Th1 response in the spleen. However, it 
repeatedly did in the lymph nodes as well as in the spleen in a previous experiment 
(Fig. 32). On the other hand, HES was clearly unable to modulate the Pa-induced 
IL-17 production. 
Thus, even if not perfect, taken together, these results seem to indicate that HES 
and hiHES possess immunomodulatory properties in our in vivo transfer model. 
HES and hiHES-pulsed DCs were able to polarise T cells toward a Th2-type 
response. However, this response was only seen upon non-specific re-stimulation 
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and the HES-specific response gave very different outcomes throughout the 
experiments, indicating that the experimental setup still needs improvements. The 
ability of HES to skew the response to a bystander antigen toward a less 
inflammatory one was also suggested even though not proven. Interestingly, the 
immunomodulatory properties of hiHES, that induced the same in vivo effects as 
HES with the exception of HES-induced IL-17, but did not affect the post-incubation 
activation state of DCs, proves that the cytokine production profile and co-
stimulatory markers expression are not directly correlated with the final outcome of 
the adaptive immune response. This suggests that the DC response to H. polygyrus 
products is dynamic, with outcomes at the infection site during the first hours of 
contact with the pathogen products different from the later effects in the lymph 
nodes when T cells are activated. Whether this is an optimised response of the 
mouse or a real immunomodulation by the pathogen remains to be determined. 
Even if the real impact of HES on the adaptive immune response to H. polygyrus 
needs further studies to be fully understood, we would like to focus now on the 
molecular aspects of the interactions between HES and dendritic cells, as this was 
the main topic of this project. 
In this work, we confirmed that the incubation of bone-marrow derived DCs with 
HES does not affect the activation state of the cells as measured by their cytokine 
production and co-stimulatory surface marker expression, but that the addition of 
this parasite product on DCs activated with different TLR ligands limits the 
expression of those markers as well as the production of TNFα, IL-6 and IL-12, 
especially the active heterodimeric form referred to as p70. This strong reduction of 
cytokine levels is an ideal read-out for functional assays on HES in the search for 
the immunoactive product(s) because it allows one to clearly differentiate total, 
partial or null effects. Moreover, DCs are crucial in the early and late innate 
response to parasites, since their cytokine production profile will locally affect the 
lamina propria environment by modifying the inflammation state of the tissue and 
attracting or not other immune cell type. DCs also migrate to lymph nodes where 
they will interact with T cells and therefore polarise the adaptive response. In 
addition, the stimulation of DCs with products such as LPS or CpG is relevant to the 
real infection by intestinal helminths, since these parasites alter the gut structure 
and permeability [59] and therefore expose DCs to bacterial products. So, this 
model has great advantages and should be used for further studies, but 
unfortunately, it also has drawbacks. First, the in vitro culture provides only one type 
of DCs which is perfect for in vitro assays, but do not represent the complexity of the 
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dendritic cells populations present in the intestinal micro-environment. For example, 
we have, for now, no idea of the response of plasmacytoid DCs to H. polygyrus 
products. Second, the opportunity to transfer DCs in vivo may be more relevant to 
the actual H. polygyrus infection than in vitro assays, but it could be biased toward a 
Th2- type response induction when naïve DCs are injected. Thus, a reliable 
negative control is lacking. Finally, a major problem during this project was the 
achievement of a reproducible phenotype and a decent yield from the in vitro 
cultures. Apparently, even very minor changes in the protocol had an impact on the 
cell phenotype and one more substantial change even affected the cytokine 
production. Therefore, in order to obtain comparable results, the greatest care must 
be given to the BMDC culture. 
Once we had a well-characterised model, we considered two approaches to our 
problem. As for any host-parasite interactions study, we could either focus on the 
host, in our case the dendritic cells, or on the parasite, here more specifically its 
excretory/secretory products. First, we investigated three signalling pathways based 
on evidence of their implication in immunomodulatory processes in other parasite 
models or in other cell types. The TGFβ pathway was the most obvious target as 
Grainger reported its fundamental role in the de novo induction of Foxp3 in CD4+ T 
cells [39]. However, our results strongly suggested that this pathway is not used to 
modulate DCs cytokines production. Of course, as mentioned before, further work 
on TGFβ receptor deficient DCs is needed to definitely prove this conclusion. In 
addition, this does not mean that the TGFβ homologue present in HES does not 
affect DCs at all. It could for example, affect pathways that do not alter the activation 
state of the DC directly, but could modify antigen presentation or other interactions 
with any kind of immune cells, resulting in a modified systemic response like the 
alteration of the response to P. acnes we described before. Again, a knockout 
model would be ideal to study this possibility. 
Then, we looked at the implication of the C-type lectin receptors. Since we had not 
enough time to study them all, we chose to investigate the role of Dectin-1 and -2 
and the ITAM-binding kinase Syk that offers the opportunity to target several CLR, 
including Mincle, CLEC-2 and BDCA-2 [60, 61], in one experiment. The choice of 
Dectin-2 was motivated by a paper by Ritter et al. [31] showing interactions between 
this CLR and Schistosoma mansoni antigens whereas Dectin-1 was reported to 
modulate the cytokine response to fungal products [45]. No recovery of cytokine 
levels was seen upon antibody-mediated blockage of both Dectin-1 and Dectin-2 or 
in the Dectin-1-/- DCs. Moreover, the two Syk inhibitors tested failed to enhance the 
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cytokine production upon LPS and HES co-treatment. Therefore, on top of ruling out 
roles for Dectin-1 or -2 in the DCs modulation by H. polygyrus products, we can also 
suggest that Syk signalling, and thus other CLRs like Mincle, CLEC-2 or BDCA-2, 
are not needed. 
Nevertheless, the C-type lectin receptor family remains a major target for 
immunomodulation studies because of the numerous descriptions of modification of 
DC responses to pathogens by these molecules and because several of them signal 
through Syk-independent pathways. Amongst them, it would be particularly 
interesting to investigate in detail the dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN), as its ligation has been shown to 
induce the phosphorylation of serine 276 on the p65 subunit of NF-κB, leading to 
the acetylation of this molecule. Strikingly, ManLAM, a cell wall component of 
mycobacteria that binds DC-SIGN, did not induce p65 translocation to the nucleus 
on its own, but was able to modify the cytokine response to the whole pathogen 
when p65 translocation was induced by TLR ligation. Salp15, another DC-SIGN 
ligand produced by ticks was reported to limit the TLR2/4-induced IL-6, IL-12 and 
TNFα production [62]. However, DC-SIGN was not the only molecule reported to 
reduce the cytokine response to TLR ligation. A very similar effect was observed 
with the mannose receptor (MR) [63]. Thus, as these features of DC-SIGN and MR 
signalling seem to fit particularly well the effects observed upon LPS and HES co-
treatment, we would suggest these CLRs as targets for future studies. Related to 
this, a good kinase target could be Raf-1, since the DC-SIGN signalling has been 
shown to be completely dependent on this molecule [62]. 
The next part of our work focussed on the TLR pathway. As mentioned in the 
introduction, this pathway is crucial for the recognition of pathogens by the innate 
immune cells and is likely to detect at least some HES molecules. Since at least 13 
TLRs have been discovered, the best way to start the study of the pathway was to 
alter crucial adapter molecules downstream of the receptors themselves to avoid 
having to block them one by one. In the case of the TLRs, the task was easier than 
for the CLRs, as the disruption of the activity of only two molecules, MyD88 and 
TRIF, was sufficient to block totally the whole pathway. The difficulty, here, was the 
direct involvement of the pathway in the LPS driven immunomodulation assay. 
Thus, we could only block one adapter at a time to allow some signalling to induce 
cytokines, or we could find another TLR-independent way to activate DCs. The 
experiments on MyD88-/- and TRIF-/- gave us first evidence that HES does not need 
any TLR to skew the DC inflammation state. After having showed that the CD40 
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ligation model could be used in our setting, we were able to use MyD88-/-xTRIF-/- 
BMDCs and confirm the results obtained with the single knockouts. Nevertheless, 
this experiment was performed only once and the CD40 ligation did not induce a 
significant up-regulation of the co-stimulatory markers used as read-out. Thus, our 
statement still needs confirmation. 
In addition to these two adapter molecules, we also wanted to characterise the 
signalling of the HES immunomodulation at the level of cytoplasmic kinases, as we 
did with Syk for the CLR signalling. Several pathways, mostly involving molecules 
from the MAPK family could be targeted. Nevertheless, molecules such as 
extracellular signal-regulated kinase (ERK) seem to regulate DCs survival rather 
than their activation [64]. Therefore, based on the previously cited papers [21-24], 
we began this study by investigating the role of PI3K, a kinase crucial for the 
regulation of cell survival, proliferation and motility that is also involved in the 
regulation of the immune response through modulation of the NF-κB activity which 
is mostly responsible for the early response to pathogen products. In several 
experiments, different concentrations of the PI3K inhibitor wortmannin were tested. 
The results indicated no modification of the immunomodulatory properties of HES 
suggesting that this kinase was unnecessary for the modulation. Thus, the next 
studies on this subject could focus on the importance of other parallel signalling 
cascade. Phosphorylation states of different kinases of the MAPK pathways could, 
for example, be assessed by western blots and compared between populations of 
DCs exposed to LPS, HES or both products. Besides the classical targets of this 
pathway, like MEK/ERK or p38, it would be particularly interesting to measure the 
phosphorylation of Raf-1 according to its importance in the CLR signalling. 
Alternatively, future work could also consider studying the suppressor of cytokine 
signalling (SOCS) family members. SOCS2, for example, has been very recently 
shown to be an important modulator of the Schistosoma mansoni induced Th2 
response [65]. 
Next, leaving the DCs aside for a while we tried to reduce the number of potential 
HES immunomodulators which is now around 370, that is the total number of protein 
identities found in HES. To do so, we had the opportunity to use already prepared 
HES size fractions in our immunomodulation assay. We repeatedly showed that a 
few fractions (mainly 10 and 14) concentrated the immunomodulatory properties 
and therefore that a fractionation followed by functional assays was an interesting 
strategy to study the effects of HES on BMDCs. Unfortunately, we were unable to 
go much further with this approach since both the mass spectrometry and the lectin 
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binding study did not seem very efficient to select a limited number of targets. Thus, 
Professor Maizels suggested two fractionation strategies. The first one is sequential 
and consists in an ion-exchange chromatography on active size fractions to further 
separate proteins according to their charge. This approach would reduce the costs 
of mass spectrometry analyses, but would require a large amount and a strong 
immunomodulatory effect of the size fraction analysed. This should not be a 
problem for fraction 14, once size fractions will be available in a buffer allowing the 
ion-exchange step. Otherwise, a chequerboard strategy could be used for fractions 
with weaker immunomodulatory properties. Both size and charge fractions of total 
HES could be assessed in parallel functional assays that should provide ranges of 
mass and charges that concentrate a certain activity. As every single protein in HES 
is known, it could be possible to select proteins, which match the mass and charge 
of the previously highlighted ranges. Finally, another simple method to reduce the 
number of identities in a single fraction is to fractionate more. In this view, HES has 
already been fractionated in 48 size fractions instead of 24. 
Another approach, suggested at the beginning of the project, was to use flow 
cytometry in order to detect physical interactions between HES and DCs. Since we 
had no particular target amongst the HES components, we could only use a 
modified version of the total product that could allow detection with a fluorochrome-
associated antibody. Luckily, a small amount of HES had already been biotinylated 
by James Hewitson and was ready to use. In addition this product turned out to bind 
BMDCs efficiently and could therefore be used to assess the binding affinity for DCs 
from various knockout mice. 
Hewitson suggested CD24 as a target because he had discovered that HES was 
binding to B cells through this molecule (unpublished data). Our results confirmed 
that HES also binds DCs via CD24, but, in contrast to CD24-/- B cells that do not 
bind HES at all, HES is still able to bind CD24 deficient DCs to some extent. 
Therefore, we hypothesise that one or more HES components bind at least two 
receptors on the DCs surface. In terms of functional significance, future work will 
have to confirm one of the two following hypothesis. Either, as suggested by the IL-
12p70 production, HES can fully immunomodulate CD24-/- DCs, or CD24 ligation by 
HES is contributing to the reduction of inflammatory cytokines, in which case the 
immunomodulation should be less efficient on CD24-/- DCs. In any case, we have at 
least showed that CD24 is not crucial for DCs immunomodulation.  
Nevertheless, this does not mean that the HES-CD24 interaction has no effect at all. 
It could, for instance, influence DC maturation, migration, antigen presentation or T-
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cell polarisation as the cytokine profile of the DCs does not seem to correlate with 
the T helper response profile in our experiments. Therefore, they are several other 
experiments that could be performed with CD24-/- BMDCs, including maturation 
assays and in vivo transfers, to further investigate the function of the HES 
interaction with CD24. 
Regarding the HES molecules that could bind CD24, Liu et al. [53] strongly 
emphasize the role of DAMPs. They showed by coimmunoprecipitations that 
HMGB1, HSP70 or HSP90 bind CD24. Interestingly, the mass spectrometry 
analysis performed in our lab reveals that HSP70, but not the two other molecules, 
is a component of HES [66]. However, it is also found in Hex and our results clearly 
show that Hex does not bind CD24+ DCs. Moreover, according to the mass 
spectrometry HSP70 is more abundant in Hex than in HES. A difference in post-
translational modifications between the H. polygyrus HSP70 and the host HSP70 
could explain the different binding properties of HSP70, but the most probable 
hypothesis is that HSP70 is so rare in both Hex and HES in comparison to other 
HES components, that it does not influence the global binding pattern. 
The comparison of HES binding to BMDCs, BMDMs and spleen-isolated B cells 
suggest that the other receptor(s) bound by biotinylated HES is (are) highly 
expressed on bone marrow-derived macrophages, less expressed on BMDCs and 
absent from B cells surface. Regarding the C-type lectins, this rules out the DC 
immunoreceptor (DCIR), which is expressed on B cells [67] and does not argue in 
favour of the previously suggested target DC-SIGN, which is mainly expressed on 
DCs. However, the mannose receptor could fit this description as it is only 
expressed on macrophages and DCs. Moreover, the signalling of this CLR has, to 
our knowledge, not been shown to be Syk dependent and remains therefore the 
best potential target for upcoming work. However, this comparison was only 
qualitative in this setup since DCs and macrophages could not be stained at the 
same time as BMDMs were grown in 7 days whereas BMDCs needed 10 days of 
cultures. Therefore, an interesting experiment to do, when enough CD24-/- mice will 
be available, would be to grow macrophages and DCs from different mice in order to 
be able to stain both cell types simultaneously and therefore have consistent 
fluorescence values for each markers. To compare wild type DCs and macrophages 
one could also consider growing one cell type from a C57BL/6 Ly5.1 background 
and the other from a Ly5.2 background. This would allow for a direct comparison of 
both cell types by staining them in the same well. Then, these cell type-dependent 
HES binding properties could help identify the CD24 ligand in HES. 
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In conclusion, in this work we characterised the immunomodulatory effects of H. 
polygyrus on GM-CSF grown BMDCs in vitro as well as in vivo and tried to define 
through which molecular mechanism this modulation occurs. H. polygyrus 
excretory/secretory products showed an amazingly powerful ability to inhibit the 
LPS- and P. acnes extract-induced DCs inflammatory cytokines production and co-
stimulatory markers up-regulation even if added in the cell environment hours after 
the bacterial stimulus. Boiling HES for 20 minutes mainly abrogated this ability, but 
did not change the T cell response upon adoptive transfer of DCs. This suggests 
that the in vitro DCs phenotype and cytokine production profile is not sufficient to 
predict the outcome of the adaptive response in vivo. 
Based on Grainger’s work, we assessed the role of the TGFβ receptor that turned 
out not to be implicated in the immunomodulatory process. We also investigated the 
CLR and TLR pathways for their largely described abilities to induce and modulate 
the response of immune cells to pathogen-associated molecular patterns. TLRs 
were shown not to be important for the HES immunomodulation of DCs. The roles of 
two CLRs as well as one downstream kinase were ruled out, but other targets were 
defined for subsequent studies. Unfortunately, no HES compound could be picked 
as a target, but strategies were defined to achieve this goal in a near future. Finally, 
one DC surface receptor was proven to interact with HES and will maybe allow for 
the isolation of DC-binding HES molecules. 
Additional work will be needed to precisely define all the DCs receptors targeted by 
HES molecules, since CD24 is clearly not the only one. For now, we still have no 
idea of which HES compounds affect the DCs response. This question could be 
tackled with the help of HES size and charge fractions that will help to reduce the 
number of targets in functional assays. As the interaction with CD24 is now 
confirmed, this property could also be used to characterise at least one HES 
component interacting with DCs. Different CLRs remain to be studied and a 
phosphorylation analysis of intra-cellular key molecules from the MAPK, STAT or 
SOCS pathways could be started as well. The adoptive transfer protocol must also 
be optimised so that, when inhibition of the HES immunomodulation will be achieved 
in vitro, the modifying agent could also be tested in vivo. If successful these studies 
will provide new targets for vaccination against H. polygyrus and hopefully other 
human-infecting helminths. Moreover, HES active compounds could be useful basis 
for the development of new anti-inflammatory drugs that could be used against 
autoimmune or allergic diseases. 
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Appendix 
Co-­‐stimulatory	  markers	  expression	  on	  MyD88-­‐/-­‐	  and	  TRIF-­‐/-­‐	  DCs	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	   S	   1	   -­	   Co-­stimulatory	   markers	   expression	   analysis	   on	   wild	   type	   (WT),	  
MyD88-­/-­	  and	  TRIF-­/-­	  BMDCs,	  Part	  1.	  Following	  the	  assay	  described	  in	  figure	  17,	  triplicate	  wells	  were	  pooled	  and	  DCs	  were	  stained	   for	   CD11c,	  MHC	   class	   II,	   CD40,	   CD80	   and	   CD86.	   Live	   cells	   expressing	   CD11c	  were	  gated	  and	   the	  geometric	  mean	  of	   the	   fluorescence	   intensity	   (MFI)	  of	  CD40-­‐	  and	  CD86-­‐linked	   fluorophores	   was	   plotted.	   Labels	   display	   HES	   dose	   in	   µg/ml.	   Data	   are	  representative	  of	  two	  similar	  experiments.	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Figure	   S	   2	   -­	   Co-­stimulatory	   markers	   expression	   analysis	   on	   wild	   type	   (WT),	  
MyD88-­/-­	  and	  TRIF-­/-­	  BMDCs,	  Part	  2.	  Following	  the	  same	  analysis	  as	  in	  figure	  S	  1,	  MFI	  of	  CD80	  and	  MHC	  class	  II	  were	  plotted.	  Data	  are	  representative	  of	  two	  similar	  experiments.	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Figure	  S	  3	  -­	  Silver	  staining	  of	  a	  2D	  gel	  of	  HES	  size	  fraction	  14	  Ladder	  labels	  are	  the	  apparent	  protein	  molecular	  weights	  in	  kDa	  
 
Figure	  S	  4	  -­	  Silver	  staining	  of	  2D	  gels	  of	  HES	  size	  fraction	  13	  and	  15	  
84 
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Figure	  S	  5	  –	  Flow	  cytometry	  analysis	  of	  wild	  type	  BMDMs.	  In	  a	   first	  step,	  wild	  type	  BMDMs	  were	  stained	  for	  CD11b,	  CD11c,	  F4/80,	  MHC	  class	  II,	  CD24	  and	  different	  concentrations	  of	  biotinylated	  HES	  or	  biotinylated	  Hex.	  A	  secondary	  stain	  with	  streptavidin-­‐APC	  allowed	  for	  the	  detection	  of	  HES	  or	  Hex	  binding.	  Live	  cells	  were	  gated	  according	   to	   their	   forward	  and	   side	   scatters	   (first	   and	   fourth	   rows	  of	   the	  board),	  then	  their	  expression	  of	  CD11b	  and	  F4/80	  (second	  and	  fifth	  rows)	  and,	  finally,	  the	   expression	   of	   CD24	   and	   biotinylated	   HES	   (third	   row)	   or	   Hex	   (sixth	   row)	   were	  plotted	  on	   the	  x	   and	  y	   axis	   respectively.	  The	   first	   column	  shows	   the	  negative	   control	  that	  was	   not	   stained	   for	  HES	   or	  Hex.	   The	   second	   to	   sixth	   columns	  were	   respectively	  stained	  with	  0.25,	  0.5,	  1,	  2	  or	  4µg/ml	  biotinylated	  HES	  or	  Hex.	  Gates	  and	  percentages	  of	  parent	  cell	  population	  gated	  in	  are	  displayed.	  
86 
	  	  
 
	  
	  
	  
	  
	  
	  
	  
	  
 
 
 
 
Figure	  S	  6	  -­	  Flow	  cytometry	  analysis	  of	  CD24-­/-­	  BMDMs	  CD24-­‐/-­‐	  BMDMs	  were	  stained	  and	  analysed	  following	  the	  same	  protocol	  as	  in	  figure	  S	  4.	  Gates	  and	  percentages	  of	  parent	  cell	  population	  gated	  in	  are	  displayed.	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Figure	  S	  7	  -­	  Flow	  cytometry	  analysis	  of	  wild	  type	  BMDCs	  Wild	  type	  BMDCs	  were	  stained	  for	  CD11c,	  MHC	  class	  II,	  CD40,	  CD86,	  CD24	  and	  different	  concentrations	  of	  biotinylated	  HES	  or	  biotinylated	  Hex.	  The	  analysis	  was	   the	  same	  as	  for	  macrophages	  (Fig.	  S	  3	  and	  4),	  except	  that	  live	  cells	  were	  gated	  for	  their	  expression	  of	  CD11c	  instead	  of	  CD11b	  and	  F4/80.	  Gates	  and	  percentages	  of	  parent	  cell	  population	  gated	  in	  are	  displayed.	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Figure	  S	  8	  -­	  Flow	  cytometry	  analysis	  of	  CD24-­/-­	  BMDCs	  CD24-­‐/-­‐	  BMDCs	  were	  stained	  and	  analysed	  following	  the	  same	  protocol	  as	  in	  figure	  S	  5.	  Gates	  and	  percentages	  of	  parent	  cell	  population	  gated	  in	  are	  displayed.	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Figure	   S	   9	   –	   Important	  molecules	   and	   inhibitors	   of	   the	   CLR	   and	   TLR	   pathways	  
considered	  in	  this	  work.	  This	  figure	  is	  not	  exhaustive	  and	  its	  purpose	  is	  only	  to	  ease	  the	  understanding	  of	  a	  few	  paragraphs	   of	   this	   work.	   This	   schematic	   compiles	   information	   from	   papers	   cited	   in	  these	  paragraphs,	  but	  also	  from	  a	  review	  by	  Kawai	  &	  Akira	  [68].	  Inhibitors	  used	  during	  the	  project	  are	  highlighted	  in	  red.	  
90 
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